



**Final results from the Betaseron® (interferon beta-1b)
Pregnancy Registry**

| | |
|---------------------------------|---|
| Journal: | <i>BMJ Open</i> |
| Manuscript ID: | bmjopen-2013-004536 |
| Article Type: | Research |
| Date Submitted by the Author: | 22-Nov-2013 |
| Complete List of Authors: | Coyle, Patricia; Stony Brook University and MS Comprehensive Care Center, Roberts, Susan; University of North Carolina Wilmington, Clinical Research Program Scheuerle, Angela; Tesseræ Genetics, Medical Genetics Thorp, John; University of North Carolina Schools of Medicine and Public Health, Department of Obstetrics and Gynecology Albano, Jessica; INC Research LLC, Post Approval and Strategic Services Rametta, Mark; Bayer HealthCare Pharmaceuticals, |
| Primary Subject Heading: | Neurology |
| Secondary Subject Heading: | Neurology, Obstetrics and gynaecology, Pharmacology and therapeutics, Reproductive medicine |
| Keywords: | Multiple sclerosis < NEUROLOGY, interferon beta-1b, pediatrics, pregnancy, congenital abnormalities |
| | |

SCHOLARONE™
Manuscripts

only

Final results from the Betaseron[®] (interferon beta-1b) Pregnancy Registry

Authors: PK Coyle, MD;¹ S Sinclair Roberts, PhD, MPH, RN;² AE Scheuerle, MD;³ JM Thorp Jr, MD;⁴ JD Albano, PhD, MPH;⁵ MJ Rametta, DO⁶

¹Stony Brook University Department of Neurology and MS Comprehensive Care Center, Stony Brook, NY

²University of North Carolina Wilmington, Clinical Research Program, Wilmington, NC

³Tesserae Genetics, Medical Genetics, Dallas, TX

⁴University of North Carolina Schools of Medicine and Public Health, Department of Obstetrics and Gynecology, Chapel Hill, NC

⁵INC Research LLC, Post Approval and Strategic Services, Raleigh, NC

⁶Bayer HealthCare Pharmaceuticals, US Medical Affairs, Neurology, Whippany, NJ

Correspondence to:

Name: Patricia Coyle

Affiliation: Stony Brook University and MS Comprehensive Care Center

Address: HSC T12-020; SUNY at Stony Brook, Stony Brook, NY 11794-8121

Telephone number: 631-444-8188

Fax number: 631-444-1474

Email address: patricia.coyle@stonybrookmedicine.edu

Search terms: multiple sclerosis, interferon beta-1b, pediatrics, pregnancy, congenital abnormalities

Word count: 2,391 words

ABSTRACT

Objectives: Women with multiple sclerosis are often diagnosed and treated during their reproductive years. Limited data are available on the safety of treatment during pregnancy. The Betaseron[®] Pregnancy Registry prospectively monitored women exposed to interferon beta-1b (IFNB-1b) during pregnancy to estimate the rates of birth defects, spontaneous abortions (SABs), and other negative outcomes in this population.

Design: From 2006-2011, this observational registry enrolled women exposed prior to conception or during pregnancy (but prior to or without abnormalities on prenatal screening). Follow-up continued from enrollment through the 4-month pediatric visit.

Setting: Patients in the United States who met these criteria were enrolled in the registry.

Results: The registry enrolled 99 pregnant women; 4 were lost to follow up. The earliest exposure to IFNB-1b occurred during the first trimester for 95 pregnancies and the third trimester for 1 pregnancy. There were 99 birth outcomes (3 twins), including 86 (86.9%) live births, 11 (11.1%) SABs, and 2 (2.0%) stillbirths. Birth defects were reported in 5 (5.1%) cases. Rates of birth defects and SAB were not significantly different from population comparators. No developmental concerns were identified at the 4 month pediatric visit.

Conclusions: The small sample size limits the ability to draw definitive conclusions; however, there was no pattern to suggest increased negative outcomes with IFNB-1b.

ARTICLE SUMMARY

Strengths and limitations of this study

- The Betaseron Pregnancy Registry contains the largest sample of interferon beta-1b-exposed pregnancies collected to date
- The smaller than expected sample size limits the ability to draw definitive conclusions; however, there was no pattern to suggest increased negative outcomes with interferon beta-1b
- Limitations of the Betaseron Pregnancy Registry include the potential for underreporting or differential reporting of outcomes due to the exclusion of retrospective patients
- Birth defect ascertainment was limited relative to population-based public health programs
- Data on infant outcomes were only collected for up to 4 months, reducing the ability of the registry to measure developmental progress

INTRODUCTION

Multiple sclerosis (MS) is a chronic demyelinating and neurodegenerative disorder that affects over 400,000 people in the United States.^{1,2} MS is much more common in women than men, and diagnosis frequently occurs when patients are in their 20s and 30s.^{3,4} Consequently, women of child-bearing age constitute a considerable portion of all patients with MS. Furthermore, up to 10% have disease onset during pregnancy.¹

The approved disease-modifying treatments (DMTs) for patients with MS have been given pregnancy category ratings of B, C, D, or X by the US Food and Drug Administration based on clinical experience and/or preclinical data (see Table 1 for pregnancy categorizations of currently-approved DMTs and a definition of different pregnancy classifications).⁵⁻¹⁴ The safety of these agents during pregnancy is a major concern given the patient profile outlined above. However, data on pregnancy outcomes in DMT-exposed patients is limited. Among the beta interferons, this is particularly true for interferon beta-1b (Betaseron[®]/Betaferon[®]; Bayer HealthCare Pharmaceuticals; Whippany, NJ).

Table 1. Pregnancy classifications of disease modifying treatments (DMTs) approved for use by patients with MS.

| Disease-modifying therapy | Pregnancy category |
|---|--------------------|
| Glatiramer acetate (Copaxone [®]) ⁹ | B |
| Interferon beta-1b (Betaseron [®] /Betaferon [®] ; Extavia [®]) ^{5,14} | C |
| Intramuscular interferon beta-1a (Avonex [®]) ⁷ | C |
| Subcutaneous interferon beta-1a (Rebif [®]) ¹¹ | C |

| | |
|--|---|
| Fingolimod (Gilenya [®]) ⁸ | C |
| Dimethyl fumarate (Tecfidera [®]) ¹³ | C |
| Natalizumab (Tysabri [®]) ⁶ | C |
| Mitoxantrone ^{6,10} | D |
| Teriflunomide (Aubagio [®]) ^{6,10,12} | X |
| FDA pregnancy categories ¹⁵ <ul style="list-style-type: none"> • Category A: No evidence of adverse effects in studies of pregnant humans • Category B: No studies from humans, but no evidence of adverse effects in studies of pregnant animals; or negative effects observed in animal models but no evidence of adverse effects in humans • Category C: Insufficient evidence from human studies, but research with pregnant animals identified some medication-related negative outcomes; in some situations, the medication may be more beneficial than harmful • Category D: Medication-related negative outcomes in human studies but medication may be needed in some situations • Category X: Medication-related negative outcomes in human or animal studies; there are no situations in which the medicine should be used | |

No teratogenic effects were seen in studies of pregnant rhesus monkeys exposed to interferon beta-1b. However, dose-related abortifacient activity was seen at doses from 0.028 mg/kg/d to 0.42 mg/kg/d, which is 2.8 to 4.0 times the recommended human dose based on surface area comparison.⁵ Although data on human exposure during pregnancy are limited, patients are advised to discontinue treatment with interferon beta-1b if they become pregnant or plan to become pregnant.⁵ The goal of the Betaseron Pregnancy Registry was to compare pregnancy outcomes in women

1
2
3 exposed to interferon beta-1b at conception or during pregnancy relative to general
4 population comparators. This is the largest observational study reported to date for
5
6 interferon beta-1b.
7
8
9

10 11 12 13 14 **METHODS**

15 16 17 **Population and outcome measures**

18
19
20 The Betaseron Pregnancy Registry was a voluntary, prospective, observational,
21 exposure-registration and follow-up study. Women with an existing pregnancy who had
22 been exposed to interferon beta-1b at any time after the first day of the last menstrual
23 period (LMP), or during pregnancy but before any prenatal screening (eg, ultrasound,
24 amniocentesis), were prospectively enrolled in the registry. Women with similar
25 exposure who had undergone some prenatal testing and were without abnormal
26 findings suggestive of fetal abnormalities were also enrolled. Because retrospective
27 cases (ie, pregnancies submitted after the birth of the infant) can be biased toward
28 reporting of unusual or severe outcomes, these cases and those in which an
29 abnormality was identified prior to registry contact were excluded.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

45 The primary outcome measure was the prevalence of major congenital malformations in
46 infants exposed to interferon beta-1b during gestation, defined as any time after the first
47 day of the mother's LMP. Secondary outcome measures included the prevalence of
48 spontaneous abortion and other negative pregnancy outcomes in exposed women.
49
50 Prevalence of elective abortion, stillbirth, ectopic pregnancy, neonatal death, and
51 maternal death was assessed. Reporting was conducted by health care providers
52
53
54
55
56
57
58
59
60

1
2
3 (HCPs), patients, or representatives of the study sponsor. Maternal follow-up lasted
4
5 from enrollment through pregnancy outcome. Infant follow-up continued through the 4-
6
7 month pediatric visit in most cases.
8
9

10
11 Pregnancy outcomes were classified as live birth, spontaneous abortion, elective
12
13 abortion, or fetal death/stillbirth. A live birth was defined as any delivery resulting in a
14
15 viable neonate ≥ 24 weeks of gestation. The spontaneous loss of a fetus at < 20 weeks
16
17 of gestation was classified as a spontaneous abortion. Any fetus delivered dead ≥ 20
18
19 weeks of gestation, or weighing ≥ 500 g regardless of gestational age, was classified as
20
21 a stillbirth. Fetal death occurring > 20 weeks but < 28 weeks was classified as early fetal
22
23 loss while death occurring ≥ 28 weeks was considered late fetal loss. Elective abortions
24
25 encompassed any induced or voluntary ending of the pregnancy. Other pregnancy
26
27 outcomes included ectopic pregnancies, maternal death, and neonatal death. Infant size
28
29 was classified as “small,” “appropriate,” or “large” for gestational age based on HCP
30
31 assessment.
32
33
34
35
36
37

38 Birth defects were defined as any significant structural or chromosomal defect
39
40 diagnosed with signs/symptoms using the Metropolitan Atlanta Congenital Defects
41
42 Program (MACDP) classification of birth defects, or any case with 2 or more secondary
43
44 or “conditional” abnormalities that would not have been classified as primary birth
45
46 defects by MACDP. Birth defects were coded using a version of the coding system of
47
48 the British Pediatric Association (BPA) in which the BPA code list was modified to
49
50 increase the possibility of detecting a potential signal by grouping similar defect or
51
52 defects with similar etiology together.¹⁶ All codes were sorted into the appropriate organ
53
54 system classes¹⁶ by an expert in dysmorphology (AES) who evaluated the potential
55
56
57
58
59
60

1
2
3 temporal relationship with exposure to interferon beta-1b. Defects were classified as
4
5 “Defect with a known cause, temporality may be irrelevant;” “No temporal association;”
6
7 or “Unable to assess temporality.”
8
9

10
11 Conduct of the registry was overseen by an independent review board. The Western
12
13 Institutional Review Board (WIRB) reviewed and approved the protocol, which included
14
15 a waiver of documentation of informed consent. The Betaseron Pregnancy Registry was
16
17 listed in the public trials registry (www.clinicaltrials.gov) under NCT00317564.
18
19

20 21 **Statistical procedures**

22
23
24 Analyses were conducted on all prospective evaluable cases (ie, enrolled pregnancies,
25
26 not lost to follow-up, with known outcome and birth defect status). Prevalence of birth
27
28 defects was calculated using the number of live births as the denominator and 95%
29
30 exact confidence intervals (CI) were calculated for point estimates. Outcome data were
31
32 stratified by the earliest trimester of exposure to interferon beta-1b. Comparator
33
34 populations were used for 2 outcomes. Risk of negative spontaneous abortions was
35
36 compared with estimates for the general population of the United States from the
37
38 National Survey of Family Growth (NSFG), which was conducted by the National Center
39
40 for Health Statistics,¹⁷ using Fisher’s exact test based on binomial distribution for
41
42 exposures. Risk for birth defects was compared with that reported by the MACDP.^{18,19}
43
44 This population-based birth defect surveillance system includes all infants born in the
45
46 metropolitan area of Atlanta, Georgia. From 1999 to 2003, the MACDP estimated the
47
48 birth defect prevalence to be 2.78 birth defects per 100 live births in its database.^{18,19}
49
50
51
52
53
54

55 56 **Role of the funding source**

1
2
3 The study was jointly designed by members of the data safety monitoring board and the
4 study sponsor. The authors had access to all the data, participated in analysis and
5 interpretation, and were members of the publication committee. The decision to submit
6 the article for publication was made jointly by the members of the steering committee.
7
8
9
10
11
12
13
14
15
16

17 RESULTS

18 Patient disposition

19
20
21
22
23 Between April 24, 2006 and July 31, 2011, 99 pregnant women were prospectively
24 enrolled in the Betaseron Pregnancy Registry. Follow-up of pregnant women and their
25 live-born infants continued through July 16, 2012. Pregnancy outcomes were reported
26 for 96 exposed pregnancies, with 3 pregnancies lost to follow-up (Table 2). Initial
27 exposure to interferon beta-1b occurred in the first trimester for 95 patients, and in the
28 third trimester for 1 patient. Seventy-four patients had pediatric follow up. For the
29 remaining 22 patients, follow-up continued only until birth. Prenatal testing prior to
30 enrollment was reported in 33 cases (34.4%).
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

48 **Table 2.** Maternal demographics.

| | Analysis population (N=96) |
|---------------------------|---------------------------------------|
| Age at enrollment (years) | |
| n | 95 |
| Mean (SD) | 30.9 (5.29) |

| | |
|--|--------------|
| Median (range) | 31.0 (19-44) |
| Age category, n (%) | |
| ≤19 years | 1 (1.0) |
| 20-34 years | 69 (71.9) |
| ≥35 years | 25 (26.0) |
| Missing | 1 (1.0) |
| Race/ethnicity, n (%) | |
| White | 62 (64.6) |
| Black | 25 (26.0) |
| Hispanic | 2 (2.1) |
| Asian | 0 (0) |
| Other | 6 (6.3) |
| Missing | 1 (1.0) |
| MS duration at enrollment, n (%) | |
| <1 year | 23 (24.0) |
| 1-5 years | 51 (53.1) |
| 6-10 years | 11 (11.5) |
| >10 years | 6 (6.3) |
| Missing | 5 (5.2) |
| Earliest trimester of exposure, ^a n (%) | |
| First | 95 (99.0) |
| Second | 0 (0) |
| Third | 1 (1.0) |
| Prenatal tests, n (%) | |
| Prenatal test(s) after enrollment | 53 (55.2) |
| Prenatal test(s) prior to enrollment | 33 (34.4) |
| Date of prenatal test(s) not provided | 1 (1.0) |
| No prenatal tests | 7 (7.3) |
| Missing/unknown | 2 (2.1) |

1
2
3^a First trimester exposure was initial exposure occurring from the first day of the LMP
4 through 13 weeks gestation; third trimester exposure was initial exposure occurring in
5 the 28th week through the end of the pregnancy.
6
7
8
9

10
11
12
13
14 The majority of the sample was white (62 patients [64.6%]); 25 patients (26.0%) were
15 black. In addition, 2 patients (2.1%) were Hispanic while 6 patients were of other
16 races/ethnicities (6.3%) and race/ethnicity data were missing for 1 patient (1.0%). Note
17 that the distribution of race/ethnicity in the Betaseron Pregnancy Registry was different
18 from population norms in the United States (72.4% white, 12.6% black, 16.3%
19 Hispanic).²⁰
20
21
22
23
24
25
26
27
28

29 **Pregnancy outcomes**

30
31
32 There were a total of 99 birth outcomes available, including 3 sets of twins. These
33 outcomes included 86 live births, 2 stillbirths, and 11 spontaneous abortions (Table 3).
34 Both stillbirths occurred in black women with a history of prior spontaneous abortion and
35 other comorbidities that may have affected birth outcomes. The first case, ending in
36 stillbirth, reported hypertension, obesity (post gastric bypass), and oligohydramnios. The
37 second reported antiphospholipid antibody syndrome, maternal human papillomavirus
38 infection, early rupture of membranes attributed to vaginal bacterial infection, and
39 preterm labor and delivery attributed to incompetent cervix. The prevalence of
40 spontaneous abortion in the Betaseron Pregnancy Registry (11.5% [95% CI 5.9–19.6])
41 was not significantly different from the 16% estimate for the general population of the
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

United States based on NSFG data (relative risk 0.7 [95% CI 0.4–1.2], P=.86, Fisher's exact test based on binomial distribution for exposures).

Table 3. Pregnancy outcomes in the Betaseron Pregnancy Registry.

| Outcomes, n (% , 95% CI) | Interferon beta-1b– exposed pregnancies | Relative risk (RR) (95% CI) |
|-----------------------------------|--|---|
| Live births (N=96) | 83 (86.4%) | - |
| Birth defects (N=86) ^a | 5 (5.8%, 1.9–13.0) | RR (95% CI) 2.1 (0.9–4.9), P=0.092 ^b |
| Spontaneous abortions (N=96) | 11 (11.5%, 5.9–19.6) | RR (95% CI) 0.7 (0.4–1.2) P=0.8603 ^c |
| Stillbirth (N=96) | 2 (2.1) | - |
| Maternal deaths | 0 (0) | - |
| Infant deaths | 0 (0) | - |
| Ectopic pregnancies | 0 (0) | - |

^a Excludes spontaneous and elective abortions <20 weeks gestation with reported birth defects per MACDP convention. The denominator is restricted to live births.

^b Relative risk compared with 2.78% reported by MACDP; Fisher's exact test based on binomial distribution for exposures.^{18,19}

^c Relative risk compared with 16.0% rate of SAB reported by NSFG; Fisher's exact test.²¹

Infant assessments were made at birth for 86 babies, up to 3 months of age for 74 babies, and at 4 months for 59 babies (Table 4). HCPs assessed infant size as appropriate for gestational age at birth for 67 cases (77.9%). Four-month follow-up did not identify any consistent pattern of developmental abnormalities. Birth defects were identified in 5 cases (Table 5), resulting in a relative risk of 2.1 (95% CI 0.9–4.9). The

1
2
3 reported birth defects occurred in several different organ systems, including the
4 musculoskeletal, cardiovascular, and circulatory systems, with no pattern to the organ
5 systems affected. For all cases reporting birth defects, the earliest exposure to
6 interferon beta-1b 250 micrograms dosed every other day occurred during the first
7 trimester of gestation. No birth defects were reported among the spontaneous
8 pregnancy losses or stillbirths. The birth defect prevalence estimated by the Betaseron
9 Pregnancy Registry (5.8% [95% CI 1.9–13.0]) was not significantly different (note the
10 overlapping confidence intervals in data from the Betaseron Pregnancy Registry) from
11 that reported by MACDP (2.78%, $P=.092$, Fisher's exact test).
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

Table 4. Infant assessments at birth and at 4 months.

| | At birth | At 4-month follow-up | Approximate median in US population at birth ²² |
|---------------------------------|--------------|----------------------|--|
| Number of infants | 86 | 59 | |
| Sex, n (%) | | | |
| Female | 40 (46.5) | 26 (44.1) | |
| Male | 46 (53.5) | 33 (55.9) | |
| Infant weight, g | | | |
| Median | 3346.8 | 6747.0 | 3200-3600 |
| Range | 470.0-4593.0 | 4763.0-8902.0 | |
| Infant size, n (%) ^a | | | |
| Small | 7 (8.1) | 3 (5.1) | |
| Appropriate | 67 (77.9) | 48 (81.4) | |
| Large | 7 (8.1) | 6 (10.2) | |
| Missing | 5 (5.8) | 2 (3.4) | |

| | | | |
|----------------------------------|-----------|-----------|-----------|
| Infant length (cm) | | | |
| Median | 50.8 | 63.5 | 49-50 |
| Range | 30.5-55.9 | 53.3-69.3 | |
| Infant head circumference (cm) | | | |
| Median | 34.3 | 41.9 | 34.8-35.8 |
| Range | 29.5-38.1 | 37.0-44.5 | |
| Gestational age at birth (weeks) | | | |
| Median | 39.0 | NA | |
| Range | 24.0-41.0 | NA | |

^a Infant size relative to gestational age at birth and age at 4 months (± 4 weeks), respectively.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Table 5. Summary of birth defect cases

| Case | Description of the reported birth defects | Organ system | Temporality assessment |
|-------------|---|---|--|
| 1 | Live infant, male, 34 weeks gestation 1. Trisomy 21 (Down syndrome) ^a | 1. Chromosome anomaly | 1. Defect with known cause, temporality may be irrelevant |
| 2 | Live infant, male, 40 weeks gestation 1. Hemangioma (capillary hemangioma parietal area and left 3rd toe) | 1. Circulatory system | 1. Unable to assess temporality |
| 3 | Live infant, female, 39 weeks gestation 1. Hip dysplasia (defect) 2. Patent foramen ovale (conditional defect) 3. Patent ductus arteriosus (conditional defect) 4. Ventriculoseptal defect (defect) | 1. Other musculoskeletal defects 2. Heart 3. Circulatory system 4. Heart | 1. Unable to assess temporality 2. Defect with known cause, temporality may be irrelevant 3. Defect with known cause, temporality may be irrelevant 4. Defect with known cause, temporality may be irrelevant |
| 4 | Live infant, male, 36 weeks gestation 1. Abnormal shape of the head without craniosynostosis | 1. Musculoskeletal defects | 1. No temporal association |
| 5 | Live infant, male, 38 weeks gestation 1. Polydactyly | 1. Limb reduction/addition defects | 1. No temporal association |

^a The mother of this infant was older than 35 years of age.

1
2
3 Because of the relatively high percentage of black patients in the Betaseron Pregnancy
4 Registry, a subanalysis of pregnancy outcome data was conducted to compare black
5 and non-black patients. No significant differences were seen between these two
6 and non-black patients. No significant differences were seen between these two
7 populations in prevalence of birth defects or rates of spontaneous abortion. However,
8 small sample sizes in this subanalysis limit the conclusions that can be drawn from
9 these data.
10
11
12
13
14
15
16
17
18
19
20

21 **DISCUSSION**

22
23
24 This Betaseron Pregnancy Registry reported 99 outcomes in 96 evaluable pregnancies
25 (including 3 twin pregnancies), consisting of 86 live births, 2 stillbirths, and 11
26 spontaneous abortions. There were 5 cases with birth defects. The risk of spontaneous
27 abortion or birth defect was not significantly different from comparator populations. In
28 addition, no elective abortions or maternal deaths were observed and there were no
29 abnormalities in rate of prematurity or in birth weight/size. These data represent the
30 largest cohort of interferon beta-1b-exposed patients reported to date; however, the
31 sample size was still smaller than necessary to have sufficient statistical power to draw
32 definitive conclusions.
33
34
35
36
37
38
39
40
41
42
43
44
45

46 To date, several publications have discussed the results of exposure to interferon beta
47 formulations during pregnancy. A recent review of this literature suggested that beta
48 interferons may be associated with some negative outcomes,²³ a conclusion that
49 contrasts with the findings presented here. Three studies (N=88, N=69, and N=23)
50 found low birth weight in infants exposed to interferon beta formulations (either
51
52
53
54
55
56
57
58
59
60

1
2
3 interferon beta-1a or beta-1b) during gestation.²⁴⁻²⁶ Another study (N=14) found
4
5 evidence of prematurity with interferon beta exposure, but birth weight was not
6
7 significantly lower than unexposed comparators.²⁷ However, another study (N=63) did
8
9 not find evidence of low birth weight following interferon beta exposure.²⁸ Other negative
10
11 pregnancy outcomes, including a higher rate of spontaneous abortion and shorter mean
12
13 birth length, have also been associated with exposure to interferon beta
14
15 formulations.^{24,25}

16
17
18
19
20 In contrast, the Betaseron Pregnancy Registry did not find any patterns to suggest
21
22 negative pregnancy outcomes associated with interferon beta-1b exposure. It should be
23
24 noted that the 5 aforementioned studies combined subjects exposed to either interferon
25
26 beta-1a or beta-1b into a single group.²⁴⁻²⁸ Two of these studies did not provide
27
28 separate numbers of interferon beta-1a and beta-1b-exposed patients.^{24,26} In the 3
29
30 studies that divided exposure groups into interferon beta-1a and beta-1b, patients with
31
32 interferon beta-1b monotherapy exposure numbered only 10–21^{25,27,28}, thereby limiting
33
34 the statistical power to draw conclusions about the effects of interferon beta-1b on
35
36 pregnancy outcomes. The Betaseron Pregnancy Registry data reported here have the
37
38 advantage of a much larger sample size (99 outcomes).

39
40
41
42
43
44
45 The Betaseron Pregnancy Registry included pediatric follow-up, which has not been not
46
47 consistently reported: only 2 other studies have assessed pediatric outcomes. The first
48
49 (N=14) reported normal development of interferon beta-1a- or beta-1b-exposed infants
50
51 up to the 12-month milestones (walking and talking).²⁷ A later study (N=88) found no
52
53 developmental abnormalities in interferon beta-exposed infants after 2.1 years of follow-
54
55 up.²⁴ The Pregnancy Registry's findings are consistent with these previous reports and
56
57
58
59
60

1
2
3 reinforce the hypothesis that there are no obvious postnatal effects from in utero
4
5 interferon beta-1b exposure.
6
7

8
9 The potential risks associated with interferon beta-1b exposure during pregnancy, which
10
11 were not found to be significantly different from comparator cohorts in this study, need
12
13 to be considered along with the risks for patients with MS who remain untreated during
14
15 pregnancy. Prior research suggested that MS itself was not associated with increased
16
17 risk for negative pregnancy outcomes.¹ However, risk for relapses is higher after
18
19 delivery, with 20%–40% of patients experiencing a clinical relapse or worsening of the
20
21 disease in the first 3 months postpartum.¹
22
23
24
25

26 The results reported here are similar to 2 recent presentations related to intramuscular
27
28 interferon beta-1a exposure during pregnancy. In the first, no pattern suggestive of
29
30 increased negative outcomes was found in 306 pregnancies in the Avonex Pregnancy
31
32 Exposure Registry.²⁹ Similarly, post marketing surveillance (N=552) found the rate of
33
34 spontaneous abortion was consistent with the general population, with no evidence of
35
36 increased rates of birth defects.³⁰ Together with the Betaseron Pregnancy Registry, the
37
38 preponderance of data suggest no pattern of increased negative outcomes for women
39
40 and infants exposed to interferon beta formulations during pregnancy, a finding that was
41
42 supported by a recent review of the literature related to interferon beta exposure during
43
44 pregnancy (N=1105).³¹
45
46
47
48
49

50
51 This is also the first study to report on pregnancy exposure outcomes in black patients
52
53 with MS. No differences were noted based on race.
54
55
56
57
58
59
60

1
2
3 Limitations of the Betaseron Pregnancy Registry include the potential for underreporting
4 or differential reporting of outcomes due to the exclusion of retrospective patients.
5
6

7
8 However, it is important to note that data from these patients were captured through
9
10 post-marketing surveillance efforts. In addition, birth defect ascertainment was limited
11
12 relative to population-based public health programs. Lastly, data on infant outcomes
13
14 were only collected for up to 4 months, reducing the ability of the registry to measure
15
16 developmental progress.
17
18

19
20 Due to restricted sample size, definitive conclusions cannot be drawn from the
21
22 Betaseron Pregnancy Registry data. However, there was no pattern to suggest an
23
24 increased risk of birth defects in infants or an increased rate of spontaneous abortions
25
26 and preterm delivery in women after exposure to interferon beta-1b during pregnancy.
27
28 Birth weight also did not differ from population estimates and the 4 month infant follow-
29
30 up did not identify any developmental concerns. Continued monitoring through routine
31
32 post-marketing surveillance activities is recommended.
33
34
35
36
37

38 **ACKNOWLEDGMENTS**

39
40
41 We are grateful to the patients and their healthcare providers for their contributions to
42
43 the study. Additionally, we thank Robert C. Ristuccia, PhD (Precept Medical
44
45 Communications), for assistance with preparation of the manuscript (funded by Bayer
46
47 HealthCare Pharmaceuticals).
48
49
50
51
52
53

54 **COMPETING INTERESTS**

55
56
57
58
59
60

- PK Coyle has received compensation for consulting/educational activities from Aconda, Accordant, Bayer, Biogen Idec, Genentech/Roche, Genzyme/Sanofi Aventis, Merck-Serono, Mylan, Novartis, and Teva Neurosciences. She has received research funding from Actelion, Novartis, and Opexa.
- S Sinclair Roberts has received compensation for consulting activities from Bayer, Lilly, and INC Research.
- AE Scheuerle has received compensation for consulting activities from Abbott, Amylin, Bayer, Biogen Idec, INC Research, Genentech, Novartis, PPD, TAP Pharma, Roche, Teva, and UCB Pharma.
- JM Thorp has received compensation for consulting from Bayer, GlaxoSmithKline, and PPD.
- JD Albano is an employee of INC Research, the coordinating center for the Betaseron Pregnancy Registry.
- MJ Rametta is a salaried employee of Bayer HealthCare.

AUTHOR CONTRIBUTIONS

- PK Coyle: Interpreted data and actively contributed to the writing and reviewing of the submitted manuscript. Member of the data safety monitoring board
- S Sinclair Roberts: Interpreted data and actively contributed to the writing and reviewing of the submitted manuscript. Member of the data safety monitoring board
- AE Scheuerle: Interpreted data and actively contributed to the writing and reviewing of the submitted manuscript. Member of the data safety monitoring board

- JM Thorp: Interpreted data and actively contributed to the writing and reviewing of the submitted manuscript. Member of the data safety monitoring board
- J Albano: Provided oversight for the conduct of the study, including the statistical analysis, interpreted data, and actively contributed to the writing and reviewing of the manuscript
- MJ Rametta: Interpreted data and actively contributed to the writing and reviewing of the submitted manuscript. Sponsor's responsible clinician for registry

This study was funded by Bayer HealthCare Pharmaceuticals, Inc.

REFERENCES

1. Bennett KA. Pregnancy and multiple sclerosis. *Clin Obstet Gynecol*. 2005;48(1):38-47.
2. Vlahiotis A, Sedjo R, Cox ER, et al. Gender differences in self-reported symptom awareness and perceived ability to manage therapy with disease-modifying medication among commercially insured multiple sclerosis patients. *J Manag Care Pharm*. 2010;16(3):206-216.
3. Compston A, Coles A. Multiple sclerosis. *Lancet*. 2002;359(9313):1221-1231.
4. Coyle PK, Christie S, Fodor P, et al. Multiple sclerosis gender issues: clinical practices of women neurologists. *Mult Scler*. 2004;10(5):582-588.
5. Betaseron [package insert]. Montville, NJ: Bayer HealthCare Pharmaceuticals; 2010.
6. Tysabri [package insert]. Cambridge, MA: Biogen Idec Inc; 2012.
7. Avonex [package insert]. Cambridge, MA: Biogen Idec Inc; 2012.
8. Gilenya [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2012.
9. Copaxone [package insert]. Kansas City, MO: TEVA Neuroscience; 2012.
10. Mitoxantrone [package insert]. Kansas City, MO: TEVA Neurosciences; 2012.

11. Rebif [package insert]. Rockland, MA: EMD Serono; 2012.
12. Aubagio [package insert]. Cambridge, MA: Genzyme Corporation; 2012.
13. Tecfidera [package insert]. Cambridge, MA: Biogen Idec Inc; 2013.
14. Extavia [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2012.
15. US Department of Health and Human Services OoWH. Pregnancy and Medicines. Available at <http://www.womenshealth.gov/publications/our-publications/fact-sheet/pregnancy-medicines.pdf>. (accessed December 21, 2012).
16. Scheuerle A, Tilson H. Birth defect classification by organ system: a novel approach to heighten teratogenic signalling in a pregnancy registry. *Pharmacoepidemiol Drug Saf*. 2002;11(6):465-475.
17. Jones RK, Kost K. Underreporting of induced and spontaneous abortion in the United States: an analysis of the 2002 National Survey of Family Growth. *Stud Fam Plann*. 2007;38(3):187-197.
18. Correa A, Cragan J, Kucik J, et al. Metropolitan Atlanta Congenital Defects Program 40th anniversary edition surveillance report: reporting birth defects surveillance data. *Birth Defects Research (Part A)*. 2007;79:65-93.
19. Correa A, Cragan J, Kucik J, et al. Errata. *Birth Defects Research (Part A)*. 2008;82(1):41-62.
20. U.S.Census Bureau. Overview of race and Hispanic origin: 2010. <http://www.census.gov/prod/cen2010/briefs/c2010br-02.pdf>. (accessed April 2013).
21. Jones CA, Pohar SL, Warren S, et al. The burden of multiple sclerosis: a community health survey. *Health Qual Life Outcomes*. 2008;6:1.
22. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, et al. CDC growth charts: United States. *Adv Data*. 2000;(314):1-27.
23. Lu E, Wang BW, Guimond C, et al. Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review. *Neurology*. 2012;79(11):1130-1135.
24. Amato MP, Portaccio E, Ghezzi A, et al. Pregnancy and fetal outcomes after interferon-beta exposure in multiple sclerosis. *Neurology*. 2010;75(20):1794-1802.
25. Boskovic R, Wide R, Wolpin J, et al. The reproductive effects of beta interferon therapy in pregnancy: a longitudinal cohort. *Neurology*. 2005;65(6):807-811.

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
26. Weber-Schoendorfer C, Schaefer C. Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study. *Mult Scler*. 2009;15(9):1037-1042.
27. Patti F, Cavallaro T, Lo FS, et al. Is in utero early-exposure to interferon beta a risk factor for pregnancy outcomes in multiple sclerosis? *J Neurol*. 2008;255(8):1250-1253.
28. Hellwig K, Haghikia A, Rockhoff M, Gold R. Multiple sclerosis and pregnancy: experience from a nationwide database in Germany. *Ther Adv Neurol Disord*. 2012;5(5):247-253.
29. Tomczyk S, Richman S, Wallace K, et al. Final results from the AVONEX (intramuscular-beta-1a) pregnancy exposure registry. Presented at the Annual Meeting of the European Society for Research and Treatment in Multiple Sclerosis. Lyon, France. October 10-13. 2012.
30. Tomczyk S, Sperling B. Post-marketing pregnancy outcomes in patients exposed to intramuscular-interferon-beta-1a. Presented at the Annual Meeting of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France. October 10-13. 2012.
31. Hughes S, Spelman T, Gray O, et al. Exposure to interferon-beta therapy in early pregnancy: a literature review of pregnancy outcomes in women with multiple sclerosis. *J Neurol Neurosurg Psychiatry*. 2012;83:Supple 2 A17.

STROBE Statement—checklist of items that should be included in reports of observational studies

| | Item No | Recommendation |
|------------------------------|---------|---|
| Title and abstract | 1 | (a) Indicate the study's design with a commonly used term in the title or the abstract Title includes the word "registry." (b) Provide in the abstract an informative and balanced summary of what was done and what was found - complete |
| Introduction | | |
| Background/rationale | 2 | Explain the scientific background and rationale for the investigation being reported Paragraph 1 on page 4 |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses Paragraph on page 5 |
| Methods | | |
| Study design | 4 | Present key elements of study design early in the paper Pages 6-8 |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection Paragraph 2 on page 6; paragraph 1 on page 9 |
| Participants | 6 | (a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up Paragraph 2-3, page 6 |
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable Paragraph 2, page 6; paragraph 1-2 on page 7 |
| Data sources/ measurement | 8* | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group Paragraph 2, page 6 |
| Bias | 9 | Describe any efforts to address potential sources of bias Paragraph 3, page 7 |
| Study size | 10 | Explain how the study size was arrived at Paragraph 2, page 9 |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why Paragraph 2, page 8 |
| Statistical methods | 12 | (a) Describe all statistical methods, including those used to control for confounding Paragraph 2, page 8 (b) Describe any methods used to examine subgroups and interactions Paragraph 2, page 8 |

Continued on next page

Results

| | | |
|------------------|-----|--|
| Participants | 13* | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed Paragraph 2, page 9 |
| | | (b) Give reasons for non-participation at each stage Paragraph 2, page 9 |
| | | (c) Consider use of a flow diagram |
| Descriptive data | 14* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders Paragraph 2, page 9; paragraph 1 page 10; Table 2 |
| | | (b) Indicate number of participants with missing data for each variable of interest Paragraph 2, page 9; Table 2 |
| Outcome data | 15* | <i>Cohort study</i> —Report numbers of outcome events or summary measures over time Pages 11-15 |
| Main results | 16 | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included - NA Paragraph 2, page 9 |
| | | (b) Report category boundaries when continuous variables were categorized - NA Paragraph 2, page 9 |
| | | (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period - NA Paragraph 2, page 9 |
| Other analyses | 17 | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses Paragraph 1, page 16 |

Discussion

| | | |
|------------------|----|--|
| Key results | 18 | Summarise key results with reference to study objectives Paragraph 2, page 16 |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias Paragraph 1, page 16; paragraph 1, page 18 |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence Paragraph 2, page 18 |
| Generalisability | 21 | Discuss the generalisability (external validity) of the study results Paragraph 2, page 18 |

Other information

| | | |
|---------|----|--|
| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based Paragraph 1, page 8 |
|---------|----|--|

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

1
2 **Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and
3 published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely
4 available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at
5 <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is
6 available at www.strobe-statement.org.
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only



**Final results from the Betaseron® (interferon beta-1b)
Pregnancy Registry: a prospective observational study of
birth defects and pregnancy-related adverse events**

| | |
|---------------------------------|---|
| Journal: | <i>BMJ Open</i> |
| Manuscript ID: | bmjopen-2013-004536.R1 |
| Article Type: | Research |
| Date Submitted by the Author: | 21-Feb-2014 |
| Complete List of Authors: | Coyle, Patricia; Stony Brook University and MS Comprehensive Care Center, Roberts, Susan; University of North Carolina Wilmington, Clinical Research Program Scheuerle, Angela; Tesseræ Genetics, Medical Genetics Thorp, John; University of North Carolina Schools of Medicine and Public Health, Department of Obstetrics and Gynecology Albano, Jessica; INC Research LLC, Post Approval and Strategic Services Rametta, Mark; Bayer HealthCare Pharmaceuticals, |
| Primary Subject Heading: | Neurology |
| Secondary Subject Heading: | Neurology, Obstetrics and gynaecology, Pharmacology and therapeutics, Reproductive medicine |
| Keywords: | Multiple sclerosis < NEUROLOGY, interferon beta-1b, pediatrics, pregnancy, congenital abnormalities |
| | |

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13

Final results from the Betaseron® (interferon beta-1b) Pregnancy Registry: a prospective observational study of birth defects and pregnancy-related adverse events

Authors: PK Coyle, MD;¹ SM Sinclair, PhD, MPH, RN;² AE Scheuerle, MD;³ JM Thorp Jr, MD;⁴ JD Albano, PhD, MPH;⁵ MJ Rametta, DO⁶

¹Stony Brook University Department of Neurology and MS Comprehensive Care Center, Stony Brook, NY

²University of North Carolina Wilmington, Clinical Research Program, Wilmington, NC

³Tesserae Genetics, Medical Genetics, Dallas, TX

⁴University of North Carolina Schools of Medicine and Public Health, Department of Obstetrics and Gynecology, Chapel Hill, NC

⁵INC Research LLC, Post Approval and Strategic Services, Raleigh, NC

⁶Bayer HealthCare Pharmaceuticals, US Medical Affairs, Neurology, Whippany, NJ

28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43

Correspondence to:

Name: Patricia Coyle

Affiliation: Stony Brook University and MS Comprehensive Care Center

Address: HSC T12-020; SUNY at Stony Brook, Stony Brook, NY 11794-8121

Telephone number: 631-444-8188

Fax number: 631-444-1474

Email address: patricia.coyle@stonybrookmedicine.edu

44
45
46
47
48

Search terms: multiple sclerosis, interferon beta-1b, pediatrics, pregnancy, congenital abnormalities

49
50
51
52
53
54
55
56
57
58
59
60

Word count: 2,784 words

ABSTRACT

Objectives: Women with multiple sclerosis are often diagnosed and treated during their reproductive years. Limited data are available on the safety of treatment during pregnancy. The Betaseron® Pregnancy Registry prospectively monitored women exposed to interferon beta-1b (IFNB-1b) during pregnancy to estimate the rates of birth defects, spontaneous abortions (SABs), and other negative outcomes in this population.

Design: From 2006-2011, this observational registry enrolled women exposed prior to conception or during pregnancy (but prior to or without abnormalities on prenatal screening). Follow-up continued from enrollment through the 4-month pediatric visit.

Setting: Patients in the United States who met these criteria were enrolled in the registry.

Results: The registry enrolled 99 pregnant women; 3 were lost to follow up. The earliest exposure to IFNB-1b occurred during the first trimester for 95 pregnancies and the third trimester for 1 pregnancy. There were 99 birth outcomes (3 twins), including 86 (86.9%) live births, 11 (11.1%) SABs, and 2 (2.0%) stillbirths. Birth defects were reported in 5 (5.1%) cases. Rates of birth defects and SAB were not significantly different from population comparators. No developmental concerns were identified at the 4 month pediatric visit.

Conclusions: The small sample size limits the ability to draw definitive conclusions; however, there was no pattern to suggest increased negative outcomes with IFNB-1b.

ARTICLE SUMMARY

Strengths and limitations of this study

- The Betaseron Pregnancy Registry contains the largest sample of interferon beta-1b-exposed pregnancies collected to date
- The relatively small sample size limits the ability to draw definitive conclusions; however, there was no pattern to suggest increased negative outcomes with interferon beta-1b
- Limitations of the Betaseron Pregnancy Registry include the potential for underreporting or differential reporting of outcomes due to the exclusion of retrospective patients and the voluntary nature of participation
- Birth defect ascertainment was limited to data obtained from reporting health care providers; infants were not examined directly as part of the registry
- Data on infant outcomes were only collected for up to 4 months, reducing the ability of the registry to measure developmental progress, defects diagnosed beyond 4 months of age, and resolution of suspected defects reported in early infancy

INTRODUCTION

Multiple sclerosis (MS) is a chronic demyelinating and neurodegenerative disorder that affects over 400,000 people in the United States.^{1,2} MS is much more common in women than men, and diagnosis frequently occurs when patients are in their 20s and 30s.^{3,4} Consequently, women of child-bearing age constitute a considerable portion of all patients with MS. Furthermore, up to 10% have disease onset during pregnancy.¹

The approved disease-modifying treatments (DMTs) for patients with MS have been given pregnancy category ratings of B, C, D, or X by the US Food and Drug Administration based on clinical experience and/or preclinical data (see Table 1 for pregnancy categorizations of currently-approved DMTs and a definition of different pregnancy classifications).⁵⁻¹⁴ The safety of these agents during pregnancy is a major concern given the patient profile outlined above. However, data on pregnancy outcomes in DMT-exposed patients is limited. Among the beta interferons, this is particularly true for interferon beta-1b (Betaseron[®]/Betaferon[®]; Bayer HealthCare Pharmaceuticals; Whippany, NJ).

Table 1. Pregnancy classifications of disease modifying treatments (DMTs) approved for use by patients with MS.

| Disease-modifying therapy | Pregnancy category |
|---|--------------------|
| Glatiramer acetate (Copaxone [®]) ⁹ | B |
| Interferon beta-1b (Betaseron [®] /Betaferon [®] ; Extavia [®]) ^{5,14} | C |
| Intramuscular interferon beta-1a (Avonex [®]) ⁷ | C |
| Subcutaneous interferon beta-1a (Rebif [®]) ¹¹ | C |

| | |
|---|---|
| Fingolimod (Gilenya [®]) ⁸ | C |
| Dimethyl fumarate (Tecfidera [®]) ¹³ | C |
| Natalizumab (Tysabri [®]) ⁶ | C |
| Mitoxantrone ^{6,10} | D |
| Teriflunomide (Aubagio [®]) ^{6,10,12} | X |
| FDA pregnancy categories¹⁵ <ul style="list-style-type: none"> • Category A: No evidence of adverse effects in studies of pregnant humans • Category B: No studies from humans, but no evidence of adverse effects in studies of pregnant animals; or negative effects observed in animal models but no evidence of adverse effects in humans • Category C: Insufficient evidence from human studies, but research with pregnant animals identified some medication-related negative outcomes; in some situations, the medication may be more beneficial than harmful • Category D: Medication-related negative outcomes in human studies but medication may be needed in some situations • Category X: Medication-related negative outcomes in human or animal studies; there are no situations in which the medicine should be used | |

No teratogenic effects were seen in studies of pregnant rhesus monkeys exposed to interferon beta-1b. However, dose-related abortifacient activity was seen at doses from 0.028 mg/kg/d to 0.42 mg/kg/d, which is 2.8 to 4.0 times the recommended human dose based on surface area comparison.⁵ Although data on human exposure during pregnancy are limited, patients are advised to discontinue treatment with interferon beta-1b if they become pregnant or plan to become pregnant.⁵ The goal of the Betaseron Pregnancy Registry was to compare pregnancy outcomes in women

1
2
3 exposed to interferon beta-1b at conception or during pregnancy relative to general
4 population comparators. This is the largest observational study reported to date for
5
6 interferon beta-1b.
7
8
9

10 11 12 13 14 **METHODS**

15 16 17 **Population and outcome measures**

18
19
20 The Betaseron Pregnancy Registry was a voluntary, prospective, observational,
21 exposure-registration and follow-up study. Women with an existing pregnancy who had
22 been exposed to interferon beta-1b at any time after the first day of the last menstrual
23 period (LMP), or during pregnancy but before any prenatal screening (eg, ultrasound,
24 amniocentesis), were prospectively enrolled in the registry. Women with similar
25 exposure who had undergone some prenatal testing and were without abnormal
26 findings suggestive of fetal abnormalities were also enrolled. Given the widespread use
27 of early prenatal testing, restricting enrollment to women without prenatal testing would
28 have dramatically reduced the available population, hindering the success of the
29 registry.^{16,17} Because retrospective cases (ie, pregnancies submitted after the birth of
30 the infant or after evidence suggestive of an abnormality on prenatal tests) can be
31 biased toward reporting of unusual or severe outcomes, these cases and those in which
32 an abnormality was identified prior to registry contact were excluded.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51
52 The primary outcome measure was the rate of major congenital malformations in infants
53 exposed to interferon beta-1b during gestation, defined as any time after the first day of
54 the mother's LMP. Secondary outcome measures included the prevalence of
55
56
57
58
59
60

1
2
3 spontaneous abortion and other negative pregnancy outcomes in exposed women.

4
5 Prevalence of elective abortion, stillbirth, ectopic pregnancy, neonatal death, and
6
7
8 maternal death was assessed. Reporting was conducted by health care providers
9
10 (HCPs), patients, or representatives of the study sponsor. Maternal follow-up lasted
11
12 from enrollment through pregnancy outcome. Infant follow-up continued through the 4-
13
14 month pediatric visit in most cases.
15

16
17
18 Pregnancy outcomes were classified as live birth, spontaneous abortion, elective
19
20 abortion, or fetal death/stillbirth. A live birth was defined as any delivery resulting in a
21
22 viable neonate ≥ 24 weeks of gestation. The spontaneous loss of a fetus at < 20 weeks
23
24 of gestation was classified as a spontaneous abortion. Any fetus delivered dead ≥ 20
25
26 weeks of gestation, or weighing ≥ 500 g regardless of gestational age, was classified as
27
28 a stillbirth. Fetal death occurring > 20 weeks but < 28 weeks was classified as early fetal
29
30 loss while death occurring ≥ 28 weeks was considered late fetal loss. Elective abortions
31
32 encompassed any induced or voluntary ending of the pregnancy. Other pregnancy
33
34 outcomes included ectopic pregnancies, maternal death, and neonatal death. Infant size
35
36 was classified as “small,” “appropriate,” or “large” for gestational age based on HCP
37
38 assessment.
39
40
41
42
43
44

45 Birth defects were defined as any significant structural or chromosomal defect
46
47 diagnosed with signs/symptoms using the Metropolitan Atlanta Congenital Defects
48
49 Program (MACDP) classification of birth defects, or any case with 2 or more secondary
50
51 or “conditional” abnormalities that would not have been classified as primary birth
52
53 defects by MACDP. Conditional abnormalities, some of which were also referred to as
54
55 “minor birth defects”, were included if present in a cluster of 2 or more to increase the
56
57
58
59
60

1
2
3 sensitivity of monitoring and to avoid missing a potential signal. Birth defects were
4
5 coded using an organ system classification to increase the possibility of detecting a
6
7 potential signal by grouping together similar defects or defects with similar etiology.¹⁸ All
8
9 cases were coded in accordance with both the MACDP code book and the organ
10
11 system classification by an expert in dysmorphology (AES) who evaluated the potential
12
13 temporal relationship between the exposure to interferon beta-1b and the etiology of the
14
15 defect, considering other potential confounders (eg, exposure to other therapies
16
17 received during the pregnancy, maternal or paternal history of defects, underlying
18
19 disease).¹⁸ Further follow-up for birth defect cases was conducted if additional
20
21 information was needed by the dysmorphologist or the data safety monitoring board
22
23 (DSMB). Defects were classified as “Defect with a known cause, temporality may be
24
25 irrelevant;” “No temporal association;” or “Unable to assess temporality.” Available data
26
27 for each defect case were reviewed individually for potential confounders and relevant
28
29 information was evaluated and recorded.
30
31
32
33
34
35
36

37 Conduct of the registry was overseen by an independent DSMB. The Western
38
39 Institutional Review Board (WIRB) reviewed and approved the protocol, which included
40
41 a waiver of documentation of informed consent. The Betaseron Pregnancy Registry was
42
43 listed in the public trials registry (www.clinicaltrials.gov) under NCT00317564.
44
45
46

47 **Statistical procedures**

48
49
50 Analyses were conducted on all prospective evaluable cases (ie, enrolled pregnancies,
51
52 not lost to follow-up, with known outcome and birth defect status). The birth defect rate
53
54 was calculated by dividing the number of cases with birth defects among all live births
55
56
57
58
59
60

1
2
3 and fetal losses >20 weeks gestation (numerator) by the number of live births
4
5 (denominator). This approach increased the sensitivity of monitoring and may have
6
7 overestimated the true rate; however it erred on the side of caution. Since the presence
8
9 or absence of birth defects is difficult to ascertain among fetal losses, including fetal
10
11 losses in the denominator would have biased the birth defect rate downwards. Ninety-
12
13 five percent exact confidence intervals (CI) were calculated for birth defect rate and
14
15 other point estimates. Outcome data were stratified by the earliest trimester of exposure
16
17 to interferon beta-1b.
18
19
20
21

22
23 Population-based external comparator groups were used to evaluate the rates of
24
25 spontaneous abortion and birth defects in the registry. Risk of spontaneous abortions
26
27 was compared with estimates for the general population of the United States from the
28
29 National Survey of Family Growth (NSFG), which was conducted by the National Center
30
31 for Health Statistics,¹⁹ using Fisher's exact test based on binomial distribution for
32
33 exposures. Risk of birth defects was compared with that reported by the MACDP.^{20,21}
34
35 This population-based birth defect surveillance system includes all infants born in the
36
37 metropolitan area of Atlanta, Georgia. From 1999 to 2003, the MACDP estimated the
38
39 population birth defect rate to be 2.78 birth defects per 100 live births in its
40
41 database.^{20,21}
42
43
44
45
46

47
48 When the Registry was designed and launched, it aimed to enroll approximately 420
49
50 pregnant women to reach the goal of 210 live births to evaluate the primary endpoint
51
52 (risk of birth defects). This sample size was estimated to be sufficient to rule out a 2.2-
53
54 fold increase in birth defects compared to the MACDP rate of 2.78^{20,21} with 80% power
55
56 (assuming a 5% level of significance). The sample size goal of 420 pregnancies was
57
58
59
60

1
2
3 expected to result in only 210 live births because of losses to follow up, enrollment
4 failures, and a live birth rate of 62%.¹⁷. After approximately 5 years of operation,
5
6 Registry enrollment resulted in only 99 live births.
7
8
9

10 11 **Role of the funding source**

12
13
14 The study was jointly designed by members of the DSMB and the study sponsor. The
15 authors, which included both the DSMB and representatives of the sponsor, had access
16 to all the data, participated in analysis and interpretation, and were members of the
17 publication committee. The decision to submit the article for publication was made
18 jointly by the members of the steering committee and the sponsor.
19
20
21
22
23
24
25
26
27
28
29

30 **RESULTS**

31 32 **Patient disposition**

33
34
35
36
37 Between April 24, 2006 and July 31, 2011, 99 pregnant women were prospectively
38 enrolled in the Betaseron Pregnancy Registry. Follow-up of pregnant women and their
39 live-born infants continued through July 16, 2012. Pregnancy outcomes were reported
40 for 96 exposed pregnancies, with 3 pregnancies lost to follow-up (Table 2). Initial
41 exposure to interferon beta-1b occurred in the first trimester for 95 patients, and in the
42 third trimester for 1 patient. Seventy-four patients had pediatric follow up. For the
43 remaining 22 patients, follow-up continued only until birth. Prenatal testing prior to
44 enrollment was reported in 33 cases (34.4%).
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 2. Maternal demographics.

| | Analysis population (N=96) |
|--|---------------------------------------|
| Age at enrollment (years) | |
| n | 95 ^a |
| Mean (SD) | 30.9 (5.29) |
| Median (range) | 31.0 (19-44) |
| Age category, n (%) | |
| ≤19 years | 1 (1.0) |
| 20-34 years | 69 (71.9) |
| ≥35 years | 25 (26.0) |
| Missing | 1 (1.0) |
| Race/ethnicity, n (%) | |
| White | 62 (64.6) |
| Black | 25 (26.0) |
| Hispanic | 2 (2.1) |
| Asian | 0 (0) |
| Other | 6 (6.3) |
| Missing | 1 (1.0) |
| MS duration at enrollment, n (%) | |
| <1 year | 23 (24.0) |
| 1-5 years | 51 (53.1) |
| 6-10 years | 11 (11.5) |
| >10 years | 6 (6.3) |
| Missing | 5 (5.2) |
| Earliest trimester of exposure, ^b n (%) | |
| First | 95 (99.0) |
| Second | 0 (0) |
| Third | 1 (1.0) |
| Prenatal tests, n (%) | |

| | |
|---------------------------------------|-----------|
| Prenatal test(s) after enrollment | 53 (55.2) |
| Prenatal test(s) prior to enrollment | 33 (34.4) |
| Date of prenatal test(s) not provided | 1 (1.0) |
| No prenatal tests | 7 (7.3) |
| Missing/unknown | 2 (2.1) |

^a Age data were missing for 1 case.

^b First trimester exposure was initial exposure occurring from the first day of the LMP through 13 weeks gestation; third trimester exposure was initial exposure occurring in the 28th week through the end of the pregnancy.

The majority of the sample was white (62 patients [64.6%]); 25 patients (26.0%) were black. In addition, 2 patients (2.1%) were Hispanic while 6 patients were of other races/ethnicities (6.3%) and race/ethnicity data were missing for 1 patient (1.0%). Note that the distribution of race/ethnicity in the Betaseron Pregnancy Registry was different from population norms in the United States (72.4% white, 12.6% black, 16.3% Hispanic).²²

Pregnancy outcomes

From the 96 evaluable pregnancies, there was a total of 99 birth outcomes available, including 3 sets of twins. These outcomes included 86 live births, 2 stillbirths, and 11 spontaneous abortions (Table 3). Both stillbirths occurred in black women with a history of prior spontaneous abortion and other comorbidities that may have affected birth outcomes. The first case, ending in stillbirth, reported hypertension, obesity (post gastric bypass), and oligohydramnios. The second reported antiphospholipid antibody syndrome, maternal human papillomavirus infection, early rupture of membranes attributed to vaginal bacterial infection, and preterm labor and delivery attributed to

incompetent cervix. The prevalence of spontaneous abortion in the Betaseron Pregnancy Registry (11.5% [95% CI 5.9–19.6]) was not significantly different from the 16% estimate for the general population of the United States based on NSFG data (relative risk 0.7 [95% CI 0.4–1.2], $P=.86$, Fisher's exact test based on binomial distribution for exposures).

Table 3. Pregnancy outcomes in the Betaseron Pregnancy Registry.

| Outcomes, n (% , 95% CI) | Interferon beta-1b–exposed pregnancies | Relative risk (RR) (95% CI) |
|-----------------------------------|--|--|
| Live births (N=96) | 83 (86.4%) | - |
| Birth defects (N=86) ^a | 5 (5.8%, 1.9–13.0) | RR (95% CI) 2.1 (0.9–4.9), $P=0.092^b$ |
| Spontaneous abortions (N=96) | 11 (11.5%, 5.9–19.6) | RR (95% CI) 0.7 (0.4–1.2) $P=0.8603^c$ |
| Stillbirth (N=96) | 2 (2.1) | - |
| Maternal deaths | 0 (0) | - |
| Infant deaths | 0 (0) | - |
| Ectopic pregnancies | 0 (0) | - |

^a Excludes spontaneous and elective abortions <20 weeks gestation with reported birth defects per MACDP convention. The denominator is restricted to live births.

^b Relative risk compared with 2.78% reported by MACDP; Fisher's exact test based on binomial distribution for exposures.^{20,21}

^c Relative risk compared with 16.0% rate of SAB reported by NSFG; Fisher's exact test.²³

Infant assessments were made at birth for 86 babies, up to 3 months of age for 74 babies, and at 4 months for 59 babies (Table 4). HCPs assessed infant size as

appropriate for gestational age at birth for 67 cases (77.9%). Four-month follow-up did not identify any consistent pattern of developmental abnormalities. Birth defects were identified in 5 cases (Table 5), resulting in a relative risk of 2.1 (95% CI 0.9–4.9). The reported birth defects occurred in several different organ systems, including the musculoskeletal, cardiovascular, and circulatory systems, with no pattern to the organ systems affected. For all cases reporting birth defects, the earliest exposure to interferon beta-1b 250 micrograms dosed every other day occurred during the first trimester of gestation. No birth defects were reported among the spontaneous pregnancy losses or stillbirths. The birth defect rate estimated by the Betaseron Pregnancy Registry (5.8% [95% CI 1.9–13.0]) was not significantly different from that reported by MACDP (2.78%, $P=.092$, Fisher's exact test). The relatively wide confidence intervals, which include the MACDP rate, reflect the small sample size and suggest no difference between the birth defect rate from the Betaseron Pregnancy Registry and the MACDP.

Table 4. Infant assessments at birth and at 4 months.

| | At birth | At 4-month follow-up | Approximate median in US population at birth ²⁴ |
|-------------------|-----------|----------------------|--|
| Number of infants | 86 | 59 | |
| Sex, n (%) | | | |
| Female | 40 (46.5) | 26 (44.1) | |
| Male | 46 (53.5) | 33 (55.9) | |
| Infant weight, g | | | |
| Median | 3346.8 | 6747.0 | 3200-3600 |

| | | | |
|----------------------------------|--------------|---------------|-----------|
| Range | 470.0-4593.0 | 4763.0-8902.0 | |
| Infant size, n (%) ^a | | | |
| Small | 7 (8.1) | 3 (5.1) | |
| Appropriate | 67 (77.9) | 48 (81.4) | |
| Large | 7 (8.1) | 6 (10.2) | |
| Missing | 5 (5.8) | 2 (3.4) | |
| Infant length (cm) | | | |
| Median | 50.8 | 63.5 | 49-50 |
| Range | 30.5-55.9 | 53.3-69.3 | |
| Infant head circumference (cm) | | | |
| Median | 34.3 | 41.9 | 34.8-35.8 |
| Range | 29.5-38.1 | 37.0-44.5 | |
| Gestational age at birth (weeks) | | | |
| Median | 39.0 | NA | |
| Range | 24.0-41.0 | NA | |

^a Infant size relative to gestational age at birth and age at 4 months (± 4 weeks), respectively.

Table 5. Summary of birth defect cases

| Case | Description of the reported birth defects ^a | Organ system | Temporality assessment |
|------|---|---|--|
| 1 | Live infant, male, 34 weeks gestation 1. Trisomy 21 (Down syndrome) ^b | 1. Chromosome anomaly | 1. Defect with known cause, temporality may be irrelevant |
| 2 | Live infant, male, 40 weeks gestation 1. Hemangioma (capillary hemangioma parietal area and left 3rd toe) | 1. Circulatory system | 1. Unable to assess temporality |
| 3 | Live infant, female, 39 weeks gestation 1. Hip dysplasia (defect) 2. Patent foramen ovale (conditional defect) 3. Patent ductus arteriosus (conditional defect) 4. Ventriculoseptal defect (defect) | 1. Other musculoskeletal defects 2. Heart 3. Circulatory system 4. Heart | 1. Unable to assess temporality 2. Defect with known cause, temporality may be irrelevant 3. Defect with known cause, temporality may be irrelevant 4. Defect with known cause, temporality may be irrelevant |
| 4 | Live infant, male, 36 weeks gestation 1. Abnormal shape of the head without craniosynostosis | 1. Musculoskeletal defects | 1. No temporal association |
| 5 | Live infant, male, 38 weeks gestation 1. Polydactyly | 1. Limb reduction/addition defects | 1. No temporal association |

^a Gestational age data are birth ages, not age at exposure.

^b The mother of this infant was older than 35 years of age.

1
2
3 Because of the relatively high percentage of black patients in the Betaseron Pregnancy
4 Registry, a subanalysis of pregnancy outcome data was conducted to compare black
5 and non-black patients. No significant differences were seen between these two
6 populations in the rates of birth defects or rates of spontaneous abortion. However,
7 small sample sizes in this subanalysis limit the conclusions that can be drawn from
8 these data.
9
10
11
12
13
14
15
16
17
18
19
20
21

22 **DISCUSSION**

23
24 This Betaseron Pregnancy Registry reported 99 outcomes in 96 evaluable pregnancies
25 (including 3 twin pregnancies), consisting of 86 live births, 2 stillbirths, and 11
26 spontaneous abortions. There were 5 cases with birth defects. Among these 5 cases
27 were a variety of birth defects which were not clustered around a single type of defect or
28 effected organ system. In addition, 2 of these cases had defects that were not
29 temporally related to interferon beta-1b exposure (ie, the timing of the exposure was not
30 consistent with the development of the defect) and 1 had a chromosomal abnormality
31 potentially related to advanced maternal age that was classified as having no temporal
32 association to exposure. This lack of a consistent pattern suggests that there was no
33 signal for birth defects due to interferon beta-1b exposure. The risk of spontaneous
34 abortion or birth defect was not significantly different from comparator populations. In
35 addition, no elective abortions or maternal deaths were observed and there were no
36 abnormalities in rate of prematurity or in birth weight/size. These data represent the
37 largest cohort of interferon beta-1b-exposed patients reported to date; however, the
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 sample size was still smaller than necessary to have sufficient statistical power to draw
4
5
6 definitive conclusions.
7

8
9 To date, several publications have discussed the results of exposure to interferon beta
10
11 formulations during pregnancy; however none have exclusively examined interferon
12
13 beta-1b exposure. A recent review of this literature suggested that beta interferons may
14
15 be associated with some negative outcomes,²⁵ a conclusion that contrasts with the
16
17 findings presented here. Three studies, also with small sample sizes, (N=88, N=69, and
18
19 N=23) found low birth weight in infants exposed to interferon beta formulations (either
20
21 interferon beta-1a or beta-1b) during gestation.²⁶⁻²⁸ Another study (N=14) found
22
23 evidence of prematurity with interferon beta exposure, but birth weight was not
24
25 significantly lower than unexposed comparators.²⁹ However, another study (N=63) did
26
27 not find evidence of low birth weight following interferon beta exposure.³⁰ Other negative
28
29 pregnancy outcomes, including a higher rate of spontaneous abortion and shorter mean
30
31 birth length, have also been associated with exposure to interferon beta
32
33 formulations.^{26,27}
34
35
36
37
38
39

40
41 In contrast, the Betaseron Pregnancy Registry did not find any patterns to suggest
42
43 negative pregnancy outcomes associated with interferon beta-1b exposure. It should be
44
45 noted that the 5 aforementioned studies combined subjects exposed to either interferon
46
47 beta-1a or beta-1b into a single group.²⁶⁻³⁰ Two of these studies did not provide
48
49 separate numbers of interferon beta-1a and beta-1b-exposed patients.^{26,28} In the 3
50
51 studies that divided exposure groups into interferon beta-1a and beta-1b, patients with
52
53 interferon beta-1b monotherapy exposure numbered only 10–21^{27,29,30}, thereby limiting
54
55 the statistical power to draw conclusions about the effects of interferon beta-1b on
56
57
58
59
60

1
2
3 pregnancy outcomes. The Betaseron Pregnancy Registry data reported here have the
4
5 advantage of a much larger sample size (99 outcomes), albeit much lower than planned
6
7 when the registry was designed.
8
9

10
11 The Betaseron Pregnancy Registry included pediatric follow-up, which has not been not
12
13 consistently reported in other studies: only 2 other studies have assessed pediatric
14
15 outcomes.^{26,29} The first (N=14) reported normal development of interferon beta-1a- or
16
17 beta-1b-exposed infants up to the 12-month milestones (walking and talking).²⁹ A later
18
19 study (N=88) found no developmental abnormalities in interferon beta-exposed infants
20
21 after 2.1 years of follow-up.²⁶ The Betaseron Pregnancy Registry's findings are
22
23 consistent with these previous reports and reinforce the hypothesis that there are no
24
25 obvious postnatal effects from in utero interferon beta-1b exposure.
26
27
28
29

30
31 The potential risks associated with interferon beta-1b exposure during pregnancy, which
32
33 were not found to be significantly different from comparator cohorts in this study, need
34
35 to be considered along with the risks for patients with MS who remain untreated during
36
37 pregnancy. Prior research suggested that MS itself was not associated with increased
38
39 risk for negative pregnancy outcomes.¹ However, risk for relapses is higher after
40
41 delivery, with 20%–40% of patients experiencing a clinical relapse or worsening of the
42
43 disease in the first 3 months postpartum.¹
44
45
46
47

48
49 The results reported here are similar to 2 recent presentations related to intramuscular
50
51 interferon beta-1a exposure during pregnancy. In the first, no pattern suggestive of
52
53 increased negative outcomes was found in 306 pregnancies in the Avonex Pregnancy
54
55 Exposure Registry.³¹ Similarly, post marketing surveillance (N=552) found the rate of
56
57
58
59
60

1
2
3 spontaneous abortion was consistent with the general population, with no evidence of
4 increased birth defect rates.³² Together with the Betaseron Pregnancy Registry, the
5 preponderance of data suggest no pattern of increased negative outcomes for women
6 and infants exposed to interferon beta formulations during pregnancy, a finding that was
7 supported by a recent review of the literature related to interferon beta exposure during
8 pregnancy (N=1105).³³
9

10
11 This is also the first study to report on pregnancy exposure outcomes in black patients
12 with MS. No differences were noted based on race.
13

14
15 Limitations of the Betaseron Pregnancy Registry include the potential for underreporting
16 or differential reporting of outcomes due to the exclusion of retrospective patients.
17

18
19 However, it is important to note that data from these retrospective patients were
20 captured through post-marketing surveillance efforts. In addition, birth defect
21 ascertainment was limited to voluntary reports from health care providers (not unlike
22 population-based public health surveillance programs), which potentially limited the
23 level of detail needed to fully characterize a birth defect case and rule out missed or
24 misdiagnoses. Lastly, data on infant outcomes were only collected for up to 4 months,
25 reducing the ability of the registry to measure developmental progress.
26
27

28
29 Due to low sample size, definitive conclusions cannot be drawn from the Betaseron
30 Pregnancy Registry data. However, there was no pattern to suggest an increased risk of
31 birth defects in infants or an increased rate of spontaneous abortions in women after
32 exposure to interferon beta-1b during pregnancy. Infant assessments, such as birth
33 weight, birth length, and head circumference, also did not differ from population
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

estimates and the 4 month infant follow-up did not identify any developmental concerns.
Continued monitoring through routine post-marketing surveillance activities is
recommended.

For peer review only

ACKNOWLEDGMENTS

We are grateful to the patients and their healthcare providers for their contributions to the study. Additionally, we thank Robert C. Ristuccia, PhD (Precept Medical Communications), for assistance with preparation of the manuscript (funded by Bayer HealthCare Pharmaceuticals).

AUTHOR CONTRIBUTIONS

- PK Coyle: Interpreted data and actively contributed to the writing and reviewing of the submitted manuscript. Member of the data safety monitoring board
- SM Sinclair: Interpreted data and actively contributed to the writing and reviewing of the submitted manuscript. Member of the data safety monitoring board
- AE Scheuerle: Interpreted data and actively contributed to the writing and reviewing of the submitted manuscript. Member of the data safety monitoring board
- JM Thorp: Interpreted data and actively contributed to the writing and reviewing of the submitted manuscript. Member of the data safety monitoring board
- J Albano: Provided oversight for the conduct of the study, including the statistical analysis, interpreted data, and actively contributed to the writing and reviewing of the manuscript
- MJ Rametta: Interpreted data and actively contributed to the writing and reviewing of the submitted manuscript. Sponsor's responsible clinician for registry

FUNDING

This study was funded by Bayer HealthCare Pharmaceuticals, Inc.

COMPETING INTERESTS

- PK Coyle has received compensation for consulting/educational activities from Aconda, Accordant, Bayer, Biogen Idec, Genentech/Roche, Genzyme/Sanofi Aventis, Merck-Serono, Mylan, Novartis, and Teva Neurosciences. She has received research funding from Actelion, Novartis, and Opexa.
- S Sinclair Roberts has received compensation for consulting activities from Bayer, Lilly, and INC Research.
- AE Scheuerle has received compensation for consulting activities from Abbott, Amylin, Bayer, Biogen Idec, INC Research, Genentech, Novartis, PPD, TAP Pharma, Roche, Teva, and UCB Pharma.
- JM Thorp has received compensation for consulting from Bayer, GlaxoSmithKline, and PPD.
- JD Albano is an employee of INC Research, the coordinating center for the Betaseron Pregnancy Registry.
- MJ Rametta is a salaried employee of Bayer HealthCare.

DATA SHARING STATEMENT

Some unpublished data remain in the final clinical study report. The data safety monitoring board of the registry (the authors of this paper) decided these data were not necessary for publication.

References

1. Bennett KA. Pregnancy and multiple sclerosis. *Clin Obstet Gynecol*. 2005;48(1):38-47.
2. Vlahiotis A, Sedjo R, Cox ER, et al. Gender differences in self-reported symptom awareness and perceived ability to manage therapy with disease-modifying medication among commercially insured multiple sclerosis patients. *J Manag Care Pharm*. 2010;16(3):206-216.
3. Compston A, Coles A. Multiple sclerosis. *Lancet*. 2002;359(9313):1221-1231.
4. Coyle PK, Christie S, Fodor P, et al. Multiple sclerosis gender issues: clinical practices of women neurologists. *Mult Scler*. 2004;10(5):582-588.
5. Betaseron [package insert]. Montville, NJ: Bayer HealthCare Pharmaceuticals; 2010.
6. Tysabri [package insert]. Cambridge, MA: Biogen Idec Inc; 2012.
7. Avonex [package insert]. Cambridge, MA: Biogen Idec Inc; 2012.
8. Gilenya [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2012.
9. Copaxone [package insert]. Kansas City, MO: TEVA Neuroscience; 2012.
10. Mitoxantrone [package insert]. Kansas City, MO: TEVA Neurosciences; 2012.
11. Rebif [package insert]. Rockland, MA: EMD Serono; 2012.
12. Aubagio [package insert]. Cambridge, MA: Genzyme Corporation; 2012.
13. Tecfidera [package insert]. Cambridge, MA: Biogen Idec Inc; 2013.
14. Extavia [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2012.
15. US Department of Health and Human Services OoWH. Pregnancy and Medicines. Available at <http://www.womenshealth.gov/publications/our-publications/fact-sheet/pregnancy-medicines.pdf>. Accessed December 21, 2012.
16. Covington D, Roberts S, McKain L. Impact of prenatal testing on birth defect prevalence in pregnancy exposure registries. *Pharmacoepidemiol Drug Saf*. 2008;17(Supplement 1):S13.

- 1
2
3 17. US Food and Drug Administration. Guidance for industry establishing pregnancy
4 exposure registries. Available at
5 [http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/WomensHealthRe](http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/WomensHealthResearch/UCM133332.pdf)
6 [search/UCM133332.pdf](http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/WomensHealthResearch/UCM133332.pdf). Accessed February 2014.
7
8
- 9 18. Scheuerle A, Tilson H. Birth defect classification by organ system: a novel
10 approach to heighten teratogenic signalling in a pregnancy registry.
11 *Pharmacoepidemiol Drug Saf.* 2002;11(6):465-475.
12
- 13 19. Jones RK, Kost K. Underreporting of induced and spontaneous abortion in the
14 United States: an analysis of the 2002 National Survey of Family Growth. *Stud*
15 *Fam Plann.* 2007;38(3):187-197.
16
- 17 20. Correa A, Cragan J, Kucik J. Metropolitan Atlanta Congenital Defects Program
18 40th anniversary edition surveillance report: reporting birth defects surveillance
19 data. *Birth Defects Research (Part A).* 2007;79:65-93.
20
- 21 21. Correa A, Cragan J, Kucik J, et al. Errata. *Birth Defects Research (Part A).*
22 2008;82(1):41-62.
23
- 24 22. U.S.Census Bureau. Overview of race and Hispanic origin: 2010.
25 <http://www.census.gov/prod/cen2010/briefs/c2010br-02.pdf>. Accessed April 2013.
26
- 27 23. Jones CA, Pohar SL, Warren S, et al. The burden of multiple sclerosis: a
28 community health survey. *Health Qual Life Outcomes.* 2008;6:1.
29
- 30 24. Kuczumski RJ, Ogden CL, Grummer-Strawn LM, et al. CDC growth charts: United
31 States. *Adv Data.* 2000;(314):1-27.
32
- 33 25. Lu E, Wang BW, Guimond C, et al. Disease-modifying drugs for multiple sclerosis
34 in pregnancy: a systematic review. *Neurology.* 2012;79(11):1130-1135.
35
- 36 26. Amato MP, Portaccio E, Ghezzi A, et al. Pregnancy and fetal outcomes after
37 interferon-beta exposure in multiple sclerosis. *Neurology.* 2010;75(20):1794-1802.
38
- 39 27. Boskovic R, Wide R, Wolpin J, et al. The reproductive effects of beta interferon
40 therapy in pregnancy: a longitudinal cohort. *Neurology.* 2005;65(6):807-811.
41
- 42 28. Weber-Schoendorfer C, Schaefer C. Multiple sclerosis, immunomodulators, and
43 pregnancy outcome: a prospective observational study. *Mult Scler.*
44 2009;15(9):1037-1042.
45
- 46 29. Patti F, Cavallaro T, Lo FS, et al. Is in utero early-exposure to interferon beta a risk
47 factor for pregnancy outcomes in multiple sclerosis? *J Neurol.* 2008;255(8):1250-
48 1253.
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
30. Hellwig K, Haghikia A, Rockhoff M, et al. Multiple sclerosis and pregnancy: experience from a nationwide database in Germany. *Ther Adv Neurol Disord*. 2012;5(5):247-253.
 31. Tomczyk S, Richman S, Wallace K,. Final results from the AVONEX (intramuscular-beta-1a) pregnancy exposure registry. Presented at the Annual Meeting of the European Society for Research and Treatment in Multiple Sclerosis. Lyon, France. October 10-13. 2012.
 32. Tomczyk S, Sperling B. Post-marketing pregnancy outcomes in patients exposed to intramuscular-interferon-beta-1a. Presented at the Annual Meeting of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France. October 10-13. 2012.
 33. Hughes S, Spelman T, Gray O, et al. Exposure to interferon-beta therapy in early pregnancy: a literature review of pregnancy outcomes in women with multiple sclerosis. *J Neurol Neurosurg Psychiatry*. 2012;83:Supple 2 A17.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Final results from the Betaseron® (interferon beta-1b) Pregnancy Registry: a prospective observational study of birth defects and pregnancy-related adverse events

~~Final results from the Betaseron® (interferon beta-1b) Pregnancy Registry~~

Authors: PK Coyle, MD;¹ SM Sinclair-~~Roberts~~, PhD, MPH, RN;² AE Scheuerle, MD;³ JM Thorp Jr, MD;⁴ JD Albano, PhD, MPH;⁵ MJ Rametta, DO⁶

¹Stony Brook University Department of Neurology and MS Comprehensive Care Center, Stony Brook, NY

²University of North Carolina Wilmington, Clinical Research Program, Wilmington, NC

³Tesserae Genetics, Medical Genetics, Dallas, TX

⁴University of North Carolina Schools of Medicine and Public Health, Department of Obstetrics and Gynecology, Chapel Hill, NC

⁵INC Research LLC, Post Approval and Strategic Services, Raleigh, NC

⁶Bayer HealthCare Pharmaceuticals, US Medical Affairs, Neurology, Whippany, NJ

Correspondence to:

Name: Patricia Coyle

Affiliation: Stony Brook University and MS Comprehensive Care Center

Address: HSC T12-020; SUNY at Stony Brook, Stony Brook, NY 11794-8121

Telephone number: 631-444-8188

Fax number: 631-444-1474

Email address: patricia.coyle@stonybrookmedicine.edu

Search terms: multiple sclerosis, interferon beta-1b, pediatrics, pregnancy, congenital abnormalities

Word count: 2,391-784 words

ABSTRACT

Objectives: Women with multiple sclerosis are often diagnosed and treated during their reproductive years. Limited data are available on the safety of treatment during pregnancy. The Betaseron[®] Pregnancy Registry prospectively monitored women exposed to interferon beta-1b (IFNB-1b) during pregnancy to estimate the rates of birth defects, spontaneous abortions (SABs), and other negative outcomes in this population.

Design: From 2006-2011, this observational registry enrolled women exposed prior to conception or during pregnancy (but prior to or without abnormalities on prenatal screening). Follow-up continued from enrollment through the 4-month pediatric visit.

Setting: Patients in the United States who met these criteria were enrolled in the registry.

Results: The registry enrolled 99 pregnant women; 43 were lost to follow up. The earliest exposure to IFNB-1b occurred during the first trimester for 95 pregnancies and the third trimester for 1 pregnancy. There were 99 birth outcomes (3 twins), including 86 (86.9%) live births, 11 (11.1%) SABs, and 2 (2.0%) stillbirths. Birth defects were reported in 5 (5.1%) cases. Rates of birth defects and SAB were not significantly different from population comparators. No developmental concerns were identified at the 4 month pediatric visit.

Conclusions: The small sample size limits the ability to draw definitive conclusions; however, there was no pattern to suggest increased negative outcomes with IFNB-1b.

ARTICLE SUMMARY

Strengths and limitations of this study

- The Betaseron Pregnancy Registry contains the largest sample of interferon beta-1b-exposed pregnancies collected to date
- The ~~smaller than expected~~ relatively small sample size limits the ability to draw definitive conclusions; however, there was no pattern to suggest increased negative outcomes with interferon beta-1b
- Limitations of the Betaseron Pregnancy Registry include the potential for underreporting or differential reporting of outcomes due to the exclusion of retrospective patients and the voluntary nature of participation
- Birth defect ascertainment was limited ~~relative to population-based public health programs~~ to data obtained from reporting health care providers; infants were not examined directly as part of the registry
- Data on infant outcomes were only collected for up to 4 months, reducing the ability of the registry to measure developmental progress, defects diagnosed beyond 4 months of age, and resolution of suspected defects reported in early infancy

INTRODUCTION

Multiple sclerosis (MS) is a chronic demyelinating and neurodegenerative disorder that affects over 400,000 people in the United States.^{1,2} MS is much more common in women than men, and diagnosis frequently occurs when patients are in their 20s and 30s.^{3,4} Consequently, women of child-bearing age constitute a considerable portion of all patients with MS. Furthermore, up to 10% have disease onset during pregnancy.¹

The approved disease-modifying treatments (DMTs) for patients with MS have been given pregnancy category ratings of B, C, D, or X by the US Food and Drug Administration based on clinical experience and/or preclinical data (see Table 1 for pregnancy categorizations of currently-approved DMTs and a definition of different pregnancy classifications).⁵⁻¹⁴ The safety of these agents during pregnancy is a major concern given the patient profile outlined above. However, data on pregnancy outcomes in DMT-exposed patients is limited. Among the beta interferons, this is particularly true for interferon beta-1b (Betaseron[®]/Betaferon[®]; Bayer HealthCare Pharmaceuticals; Whippany, NJ).

Table 1. Pregnancy classifications of disease modifying treatments (DMTs) approved for use by patients with MS.

| Disease-modifying therapy | Pregnancy category |
|---|--------------------|
| Glatiramer acetate (Copaxone [®]) ⁹ | B |
| Interferon beta-1b (Betaseron [®] /Betaferon [®] ; Extavia [®]) ^{5,14} | C |
| Intramuscular interferon beta-1a (Avonex [®]) ⁷ | C |
| Subcutaneous interferon beta-1a (Rebif [®]) ¹¹ | C |

| | |
|--|---|
| Fingolimod (Gilenya [®]) ⁸ | C |
| Dimethyl fumarate (Tecfidera [®]) ¹³ | C |
| Natalizumab (Tysabri [®]) ⁶ | C |
| Mitoxantrone ^{6,10} | D |
| Teriflunomide (Aubagio [®]) ^{6,10,12} | X |
| FDA pregnancy categories ¹⁵ <ul style="list-style-type: none"> • Category A: No evidence of adverse effects in studies of pregnant humans • Category B: No studies from humans, but no evidence of adverse effects in studies of pregnant animals; or negative effects observed in animal models but no evidence of adverse effects in humans • Category C: Insufficient evidence from human studies, but research with pregnant animals identified some medication-related negative outcomes; in some situations, the medication may be more beneficial than harmful • Category D: Medication-related negative outcomes in human studies but medication may be needed in some situations • Category X: Medication-related negative outcomes in human or animal studies; there are no situations in which the medicine should be used | |

No teratogenic effects were seen in studies of pregnant rhesus monkeys exposed to interferon beta-1b. However, dose-related abortifacient activity was seen at doses from 0.028 mg/kg/d to 0.42 mg/kg/d, which is 2.8 to 4.0 times the recommended human dose based on surface area comparison.⁵ Although data on human exposure during pregnancy are limited, patients are advised to discontinue treatment with interferon beta-1b if they become pregnant or plan to become pregnant.⁵ The goal of the Betaseron Pregnancy Registry was to compare pregnancy outcomes in women

1
2
3 exposed to interferon beta-1b at conception or during pregnancy relative to general
4
5 population comparators. This is the largest observational study reported to date for
6
7 interferon beta-1b.
8
9

10 11 12 13 14 **METHODS**

15 16 17 **Population and outcome measures**

18
19
20 The Betaseron Pregnancy Registry was a voluntary, prospective, observational,
21
22 exposure-registration and follow-up study. Women with an existing pregnancy who had
23
24 been exposed to interferon beta-1b at any time after the first day of the last menstrual
25
26 period (LMP), or during pregnancy but before any prenatal screening (eg, ultrasound,
27
28 amniocentesis), were prospectively enrolled in the registry. Women with similar
29
30 exposure who had undergone some prenatal testing and were without abnormal
31
32 findings suggestive of fetal abnormalities were also enrolled. Given the widespread use
33
34 of early prenatal testing, restricting enrollment to women without prenatal testing would
35
36 have dramatically reduced the available population, hindering the success of the
37
38 registry.^{16,17} Because retrospective cases (ie, pregnancies submitted after the birth of
39
40 the infant or after evidence suggestive of an abnormality on prenatal tests) can be
41
42 biased toward reporting of unusual or severe outcomes, these cases and those in which
43
44 an abnormality was identified prior to registry contact were excluded.
45
46
47
48
49
50

51
52 The primary outcome measure was the prevalence-rate of major congenital
53
54 malformations in infants exposed to interferon beta-1b during gestation, defined as any
55
56 time after the first day of the mother's LMP. Secondary outcome measures included the
57
58
59
60

1
2
3 prevalence of spontaneous abortion and other negative pregnancy outcomes in
4 exposed women. Prevalence of elective abortion, stillbirth, ectopic pregnancy, neonatal
5 death, and maternal death was assessed. Reporting was conducted by health care
6 providers (HCPs), patients, or representatives of the study sponsor. Maternal follow-up
7 lasted from enrollment through pregnancy outcome. Infant follow-up continued through
8 the 4-month pediatric visit in most cases.
9

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Pregnancy outcomes were classified as live birth, spontaneous abortion, elective
abortion, or fetal death/stillbirth. A live birth was defined as any delivery resulting in a
viable neonate ≥ 24 weeks of gestation. The spontaneous loss of a fetus at < 20 weeks
of gestation was classified as a spontaneous abortion. Any fetus delivered dead ≥ 20
weeks of gestation, or weighing ≥ 500 g regardless of gestational age, was classified as
a stillbirth. Fetal death occurring > 20 weeks but < 28 weeks was classified as early fetal
loss while death occurring ≥ 28 weeks was considered late fetal loss. Elective abortions
encompassed any induced or voluntary ending of the pregnancy. Other pregnancy
outcomes included ectopic pregnancies, maternal death, and neonatal death. Infant size
was classified as “small,” “appropriate,” or “large” for gestational age based on HCP
assessment.

Birth defects were defined as any significant structural or chromosomal defect
diagnosed with signs/symptoms using the Metropolitan Atlanta Congenital Defects
Program (MACDP) classification of birth defects, or any case with 2 or more secondary
or “conditional” abnormalities that would not have been classified as primary birth
defects by MACDP. Conditional abnormalities, some of which were also referred to as
“minor birth defects”, were included if present in a cluster of 2 or more to increase the

1
2
3 sensitivity of monitoring and to avoid missing a potential signal. Birth defects were
4 coded using a version of the coding system of the British Pediatric Association (BPA) in
5 which the BPA code list was modified an organ system classification to increase the
6 possibility of detecting a potential signal by grouping together similar defects or defects
7 with similar etiology together.¹⁸ All codes were sorted into the appropriate organ system
8 classes cases were coded in accordance with both the MACDP code book and the
9 organ system classification by an expert in dysmorphology (AES) who evaluated the
10 potential temporal relationship withbetween the exposure to interferon beta-1b and the
11 etiology of the defect, considering other potential confounders (eg, exposure to other
12 therapies received during the pregnancy, maternal or paternal history of defects,
13 underlying disease).¹⁸ Further follow-up for birth defect cases was conducted if
14 additional information was needed by the dysmorphologist or the data safety monitoring
15 board (DSMB). Defects were classified as “Defect with a known cause, temporality may
16 be irrelevant;” “No temporal association;” or “Unable to assess temporality.” Available
17 data for each defect case were reviewed individually for potential confounders and
18 relevant information was evaluated and recorded.

19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42 Conduct of the registry was overseen by an independent DSMBreview board. The
43
44 Western Institutional Review Board (WIRB) reviewed and approved the protocol, which
45 included a waiver of documentation of informed consent. The Betaseron Pregnancy
46
47 Registry was listed in the public trials registry (www.clinicaltrials.gov) under
48
49
50
51
52 NCT00317564.

53 54 55 **Statistical procedures** 56 57 58 59 60

Analyses were conducted on all prospective evaluable cases (ie, enrolled pregnancies, not lost to follow-up, with known outcome and birth defect status). Prevalence of The birth defect rates was calculated by dividing the number of cases with birth defects among all live births and fetal losses >20 weeks gestation (numerator) by using the number of live births (as the denominator). This approach increased the sensitivity of monitoring and may have overestimated the true rate; however it erred on the side of caution. Since the presence or absence of birth defects is difficult to ascertain among fetal losses, including fetal losses in the denominator would have biased the birth defect rate downwards. and 95% Ninety-five percent exact confidence intervals (CI) were calculated for birth defect rate and other point estimates. Outcome data were stratified by the earliest trimester of exposure to interferon beta-1b.

Population-based external Comparator populations groups were used for 2 outcomes to evaluate the rates of spontaneous abortion and birth defects in the registry.

Risk of negative spontaneous abortions was compared with estimates for the general population of the United States from the National Survey of Family Growth (NSFG), which was conducted by the National Center for Health Statistics,¹⁹ using Fisher's exact test based on binomial distribution for exposures. Risk for of birth defects was compared with that reported by the MACDP.^{20,21} This population-based birth defect surveillance system includes all infants born in the metropolitan area of Atlanta, Georgia. From 1999 to 2003, the MACDP estimated the population birth defect prevalence rate to be 2.78 birth defects per 100 live births in its database.^{20,21}

When the Registry was designed and launched, it aimed to enroll approximately 420 pregnant women to reach the goal of 210 live births to evaluate the primary endpoint

1
2
3
4 (risk of birth defects). This sample size was estimated to be sufficient to rule out a 2.2-
5 fold increase in birth defects compared to the MACDP rate of 2.78^{20,21} with 80% power
6
7 (assuming a 5% level of significance). The sample size goal of 420 pregnancies was
8
9 expected to result in only 210 live births because of losses to follow up, enrollment
10
11 failures, and a live birth rate of 62%.¹⁷. After approximately 5 years of operation,
12
13 Registry enrollment resulted in only 99 live births.
14
15
16
17

18 **Role of the funding source**

19
20
21 The study was jointly designed by members of the data safety monitoring board-DSMB
22 and the study sponsor. The authors, which included both the DSMB and representatives
23 of the sponsor, had access to all the data, participated in analysis and interpretation,
24
25 and were members of the publication committee. The decision to submit the article for
26
27 publication was made jointly by the members of the steering committee and the
28
29 sponsor.
30
31
32
33
34
35
36
37
38
39

40 **RESULTS**

41 **Patient disposition**

42
43
44 Between April 24, 2006 and July 31, 2011, 99 pregnant women were prospectively
45
46 enrolled in the Betaseron Pregnancy Registry. Follow-up of pregnant women and their
47
48 live-born infants continued through July 16, 2012. Pregnancy outcomes were reported
49
50 for 96 exposed pregnancies, with 3 pregnancies lost to follow-up (Table 2). Initial
51
52 exposure to interferon beta-1b occurred in the first trimester for 95 patients, and in the
53
54
55
56
57
58
59
60

third trimester for 1 patient. Seventy-four patients had pediatric follow up. For the remaining 22 patients, follow-up continued only until birth. Prenatal testing prior to enrollment was reported in 33 cases (34.4%).

Table 2. Maternal demographics.

| | Analysis population (N=96) |
|----------------------------------|---------------------------------------|
| Age at enrollment (years) | |
| n | 95 ^a |
| Mean (SD) | 30.9 (5.29) |
| Median (range) | 31.0 (19-44) |
| Age category, n (%) | |
| ≤19 years | 1 (1.0) |
| 20-34 years | 69 (71.9) |
| ≥35 years | 25 (26.0) |
| Missing | 1 (1.0) |
| Race/ethnicity, n (%) | |
| White | 62 (64.6) |
| Black | 25 (26.0) |
| Hispanic | 2 (2.1) |
| Asian | 0 (0) |
| Other | 6 (6.3) |
| Missing | 1 (1.0) |
| MS duration at enrollment, n (%) | |
| <1 year | 23 (24.0) |
| 1-5 years | 51 (53.1) |
| 6-10 years | 11 (11.5) |
| >10 years | 6 (6.3) |

| | |
|--|-----------|
| Missing | 5 (5.2) |
| Earliest trimester of exposure, ^a ₋ ^b n (%) | |
| First | 95 (99.0) |
| Second | 0 (0) |
| Third | 1 (1.0) |
| Prenatal tests, n (%) | |
| Prenatal test(s) after enrollment | 53 (55.2) |
| Prenatal test(s) prior to enrollment | 33 (34.4) |
| Date of prenatal test(s) not provided | 1 (1.0) |
| No prenatal tests | 7 (7.3) |
| Missing/unknown | 2 (2.1) |

^a Age data were missing for 1 case.

^b First trimester exposure was initial exposure occurring from the first day of the LMP through 13 weeks gestation; third trimester exposure was initial exposure occurring in the 28th week through the end of the pregnancy.

The majority of the sample was white (62 patients [64.6%]); 25 patients (26.0%) were black. In addition, 2 patients (2.1%) were Hispanic while 6 patients were of other races/ethnicities (6.3%) and race/ethnicity data were missing for 1 patient (1.0%). Note that the distribution of race/ethnicity in the Betaseron Pregnancy Registry was different from population norms in the United States (72.4% white, 12.6% black, 16.3% Hispanic).²²

Pregnancy outcomes

From the 96 evaluable pregnancies, there was a total of 99 birth outcomes available, including 3 sets of twins. These outcomes included 86 live births, 2 stillbirths, and 11 spontaneous abortions (Table 3). Both stillbirths occurred in black women with a history

of prior spontaneous abortion and other comorbidities that may have affected birth outcomes. The first case, ending in stillbirth, reported hypertension, obesity (post gastric bypass), and oligohydramnios. The second reported antiphospholipid antibody syndrome, maternal human papillomavirus infection, early rupture of membranes attributed to vaginal bacterial infection, and preterm labor and delivery attributed to incompetent cervix. The prevalence of spontaneous abortion in the Betaseron Pregnancy Registry (11.5% [95% CI 5.9–19.6]) was not significantly different from the 16% estimate for the general population of the United States based on NSFG data (relative risk 0.7 [95% CI 0.4–1.2], $P=.86$, Fisher's exact test based on binomial distribution for exposures).

Table 3. Pregnancy outcomes in the Betaseron Pregnancy Registry.

| Outcomes, n (% , 95% CI) | Interferon beta-1b–exposed pregnancies | Relative risk (RR) (95% CI) |
|-----------------------------------|---|--|
| Live births (N=96) | 83 (86.4%) | - |
| Birth defects (N=86) ^a | 5 (5.8%, 1.9–13.0) | RR (95% CI) 2.1 (0.9–4.9), $P=0.092^b$ |
| Spontaneous abortions (N=96) | 11 (11.5%, 5.9–19.6) | RR (95% CI) 0.7 (0.4–1.2) $P=0.8603^c$ |
| Stillbirth (N=96) | 2 (2.1) | - |
| Maternal deaths | 0 (0) | - |
| Infant deaths | 0 (0) | - |
| Ectopic pregnancies | 0 (0) | - |

^a Excludes spontaneous and elective abortions <20 weeks gestation with reported birth defects per MACDP convention. The denominator is restricted to live births.

^b Relative risk compared with 2.78% reported by MACDP; Fisher's exact test based on binomial distribution for exposures.^{20,21}

^c Relative risk compared with 16.0% rate of SAB reported by NSFG; Fisher's exact test.²³

Infant assessments were made at birth for 86 babies, up to 3 months of age for 74 babies, and at 4 months for 59 babies (Table 4). HCPs assessed infant size as appropriate for gestational age at birth for 67 cases (77.9%). Four-month follow-up did not identify any consistent pattern of developmental abnormalities. Birth defects were identified in 5 cases (Table 5), resulting in a relative risk of 2.1 (95% CI 0.9–4.9). The reported birth defects occurred in several different organ systems, including the musculoskeletal, cardiovascular, and circulatory systems, with no pattern to the organ systems affected. For all cases reporting birth defects, the earliest exposure to interferon beta-1b 250 micrograms dosed every other day occurred during the first trimester of gestation. No birth defects were reported among the spontaneous pregnancy losses or stillbirths. The birth defect prevalence rate estimated by the Betaseron Pregnancy Registry (5.8% [95% CI 1.9–13.0]) was not significantly different (note the overlapping confidence intervals in data from the Betaseron Pregnancy Registry) from that reported by MACDP (2.78%, $P=.092$, Fisher's exact test). The relatively wide confidence intervals, which include the MACDP rate, reflect the small sample size and suggest no difference between the birth defect rate from the Betaseron Pregnancy Registry and the MACDP.

Table 4. Infant assessments at birth and at 4 months.

| | At birth | At 4-month | Approximate |
|--|----------|------------|-------------|
|--|----------|------------|-------------|

| | | follow-up | median in US population at birth²⁴ |
|----------------------------------|--------------|------------------|--|
| Number of infants | 86 | 59 | |
| Sex, n (%) | | | |
| Female | 40 (46.5) | 26 (44.1) | |
| Male | 46 (53.5) | 33 (55.9) | |
| Infant weight, g | | | |
| Median | 3346.8 | 6747.0 | 3200-3600 |
| Range | 470.0-4593.0 | 4763.0-8902.0 | |
| Infant size, n (%) ^a | | | |
| Small | 7 (8.1) | 3 (5.1) | |
| Appropriate | 67 (77.9) | 48 (81.4) | |
| Large | 7 (8.1) | 6 (10.2) | |
| Missing | 5 (5.8) | 2 (3.4) | |
| Infant length (cm) | | | |
| Median | 50.8 | 63.5 | 49-50 |
| Range | 30.5-55.9 | 53.3-69.3 | |
| Infant head circumference (cm) | | | |
| Median | 34.3 | 41.9 | 34.8-35.8 |
| Range | 29.5-38.1 | 37.0-44.5 | |
| Gestational age at birth (weeks) | | | |
| Median | 39.0 | NA | |
| Range | 24.0-41.0 | NA | |

^a Infant size relative to gestational age at birth and age at 4 months (± 4 weeks), respectively.

Table 5. Summary of birth defect cases

| Case | Description of the reported birth defects ^a | Organ system | Temporality assessment |
|------|---|---|--|
| 1 | Live infant, male, 34 weeks gestation 1. Trisomy 21 (Down syndrome) ^{ab} | 1. Chromosome anomaly | 1. Defect with known cause, temporality may be irrelevant |
| 2 | Live infant, male, 40 weeks gestation 1. Hemangioma (capillary hemangioma parietal area and left 3rd toe) | 1. Circulatory system | 1. Unable to assess temporality |
| 3 | Live infant, female, 39 weeks gestation 1. Hip dysplasia (defect) 2. Patent foramen ovale (conditional defect) 3. Patent ductus arteriosus (conditional defect) 4. Ventriculoseptal defect (defect) | 1. Other musculoskeletal defects 2. Heart 3. Circulatory system 4. Heart | 1. Unable to assess temporality 2. Defect with known cause, temporality may be irrelevant 3. Defect with known cause, temporality may be irrelevant 4. Defect with known cause, temporality may be irrelevant |
| 4 | Live infant, male, 36 weeks gestation 1. Abnormal shape of the head without craniosynostosis | 1. Musculoskeletal defects | 1. No temporal association |
| 5 | Live infant, male, 38 weeks gestation 1. Polydactyly | 1. Limb reduction/addition defects | 1. No temporal association |

^a Gestational age data are birth ages, not age at exposure.

^b The mother of this infant was older than 35 years of age.

1
2
3 Because of the relatively high percentage of black patients in the Betaseron Pregnancy
4 Registry, a subanalysis of pregnancy outcome data was conducted to compare black
5 and non-black patients. No significant differences were seen between these two
6 and non-black patients. No significant differences were seen between these two
7 populations in ~~prevalence~~ the rates of birth defects or rates of spontaneous abortion.
8
9 However, small sample sizes in this subanalysis limit the conclusions that can be drawn
10 from these data.
11
12
13
14
15
16
17
18
19
20
21

22 DISCUSSION

23
24 This Betaseron Pregnancy Registry reported 99 outcomes in 96 evaluable pregnancies
25 (including 3 twin pregnancies), consisting of 86 live births, 2 stillbirths, and 11
26 spontaneous abortions. There were 5 cases with birth defects. Among these 5 cases
27 were a variety of birth defects which were not clustered around a single type of defect or
28 affected organ system. In addition, 2 of these cases had defects that were not
29 temporally related to interferon beta-1b exposure (ie, the timing of the exposure was not
30 consistent with the development of the defect) and 1 had a chromosomal abnormality
31 potentially related to advanced maternal age that was classified as having no temporal
32 association to exposure. This lack of a consistent pattern suggests that there was no
33 signal for birth defects due to interferon beta-1b exposure. The risk of spontaneous
34 abortion or birth defect was not significantly different from comparator populations. In
35 addition, no elective abortions or maternal deaths were observed and there were no
36 abnormalities in rate of prematurity or in birth weight/size. These data represent the
37 largest cohort of interferon beta-1b-exposed patients reported to date; however, the
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 sample size was still smaller than necessary to have sufficient statistical power to draw
4
5 definitive conclusions.
6
7

8
9 To date, several publications have discussed the results of exposure to interferon beta
10
11 formulations during pregnancy; however none have exclusively examined interferon
12
13 beta-1b exposure. A recent review of this literature suggested that beta interferons may
14
15 be associated with some negative outcomes,²⁵ a conclusion that contrasts with the
16
17 findings presented here. Three studies, also with small sample sizes, (N=88, N=69, and
18
19 N=23) found low birth weight in infants exposed to interferon beta formulations (either
20
21 interferon beta-1a or beta-1b) during gestation.²⁶⁻²⁸ Another study (N=14) found
22
23 evidence of prematurity with interferon beta exposure, but birth weight was not
24
25 significantly lower than unexposed comparators.²⁹ However, another study (N=63) did
26
27 not find evidence of low birth weight following interferon beta exposure.³⁰ Other negative
28
29 pregnancy outcomes, including a higher rate of spontaneous abortion and shorter mean
30
31 birth length, have also been associated with exposure to interferon beta
32
33 formulations.^{26,27}
34
35
36
37
38
39

40
41 In contrast, the Betaseron Pregnancy Registry did not find any patterns to suggest
42
43 negative pregnancy outcomes associated with interferon beta-1b exposure. It should be
44
45 noted that the 5 aforementioned studies combined subjects exposed to either interferon
46
47 beta-1a or beta-1b into a single group.²⁶⁻³⁰ Two of these studies did not provide
48
49 separate numbers of interferon beta-1a and beta-1b-exposed patients.^{26,28} In the 3
50
51 studies that divided exposure groups into interferon beta-1a and beta-1b, patients with
52
53 interferon beta-1b monotherapy exposure numbered only 10–21^{27,29,30}, thereby limiting
54
55 the statistical power to draw conclusions about the effects of interferon beta-1b on
56
57
58
59
60

1
2
3 pregnancy outcomes. The Betaseron Pregnancy Registry data reported here have the
4
5 advantage of a much larger sample size (99 outcomes), albeit much lower than planned
6
7
8 when the registry was designed.
9

10
11 The Betaseron Pregnancy Registry included pediatric follow-up, which has not been not
12
13 consistently reported in other studies: only 2 other studies have assessed pediatric
14
15 outcomes.^{26,29} The first (N=14) reported normal development of interferon beta-1a- or
16
17 beta-1b-exposed infants up to the 12-month milestones (walking and talking).²⁹ A later
18
19 study (N=88) found no developmental abnormalities in interferon beta-exposed infants
20
21 after 2.1 years of follow-up.²⁶ The Betaseron Pregnancy Registry's findings are
22
23 consistent with these previous reports and reinforce the hypothesis that there are no
24
25 obvious postnatal effects from in utero interferon beta-1b exposure.
26
27
28
29
30

31 The potential risks associated with interferon beta-1b exposure during pregnancy, which
32
33 were not found to be significantly different from comparator cohorts in this study, need
34
35 to be considered along with the risks for patients with MS who remain untreated during
36
37 pregnancy. Prior research suggested that MS itself was not associated with increased
38
39 risk for negative pregnancy outcomes.¹ However, risk for relapses is higher after
40
41 delivery, with 20%–40% of patients experiencing a clinical relapse or worsening of the
42
43 disease in the first 3 months postpartum.¹
44
45
46
47

48 The results reported here are similar to 2 recent presentations related to intramuscular
49
50 interferon beta-1a exposure during pregnancy. In the first, no pattern suggestive of
51
52 increased negative outcomes was found in 306 pregnancies in the Avonex Pregnancy
53
54 Exposure Registry.³¹ Similarly, post marketing surveillance (N=552) found the rate of
55
56
57
58
59
60

1
2
3 spontaneous abortion was consistent with the general population, with no evidence of
4 increased ~~rates of~~ birth defect rates.³² Together with the Betaseron Pregnancy
5
6 Registry, the preponderance of data suggest no pattern of increased negative outcomes
7
8 for women and infants exposed to interferon beta formulations during pregnancy, a
9
10 finding that was supported by a recent review of the literature related to interferon beta
11
12 exposure during pregnancy (N=1105).³³
13
14
15
16

17
18 This is also the first study to report on pregnancy exposure outcomes in black patients
19
20 with MS. No differences were noted based on race.
21
22

23
24 Limitations of the Betaseron Pregnancy Registry include the potential for underreporting
25
26 or differential reporting of outcomes due to the exclusion of retrospective patients.
27

28
29 However, it is important to note that data from these retrospective patients were
30
31 captured through post-marketing surveillance efforts. In addition, birth defect
32
33 ascertainment was limited to voluntary reports from health care providers (not unlike
34
35 relative to population-based public health surveillance programs), which potentially
36
37 limited the level of detail needed to fully characterize a birth defect case and rule out
38
39 missed or misdiagnoses. Lastly, data on infant outcomes were only collected for up to 4
40
41 months, reducing the ability of the registry to measure developmental progress.
42
43
44

45
46 Due to restricted-low sample size, definitive conclusions cannot be drawn from the
47
48 Betaseron Pregnancy Registry data. However, there was no pattern to suggest an
49
50 increased risk of birth defects in infants or an increased rate of spontaneous abortions
51
52 and preterm delivery in women after exposure to interferon beta-1b during pregnancy.
53
54 Infant assessments, such as Bbirth weight, birth length, and head circumference, also
55
56
57
58
59
60

1
2
3 did not differ from population estimates and the 4 month infant follow-up did not identify
4
5 any developmental concerns. Continued monitoring through routine post-marketing
6
7 surveillance activities is recommended.
8
9

10 11 **ACKNOWLEDGMENTS**

12
13
14 We are grateful to the patients and their healthcare providers for their contributions to
15
16 the study. Additionally, we thank Robert C. Ristuccia, PhD (Precept Medical
17
18 Communications), for assistance with preparation of the manuscript (funded by Bayer
19
20 HealthCare Pharmaceuticals).
21
22
23
24
25
26

27 **COMPETING INTERESTS**

- 28
29
30 • PK Coyle has received compensation for consulting/educational activities from
31
32 Aconda, Accordant, Bayer, Biogen Idec, Genentech/Roche, Genzyme/Sanofi
33
34 Aventis, Merck-Serono, Mylan, Novartis, and Teva Neurosciences. She has
35
36 received research funding from Actelion, Novartis, and Opexa.
37
38
- 39
40 • S Sinclair Roberts has received compensation for consulting activities from
41
42 Bayer, Lilly, and INC Research.
43
- 44
45 • AE Scheuerle has received compensation for consulting activities from Abbott,
46
47 Amylin, Bayer, Biogen Idec, INC Research, Genentech, Novartis, PPD, TAP
48
49 Pharma, Roche, Teva, and UCB Pharma.
50
- 51
52 • JM Thorp has received compensation for consulting from Bayer,
53
54 GlaxoSmithKline, and PPD.
55
56
57
58
59
60

- JD Albano is an employee of INC Research, the coordinating center for the Betaseron Pregnancy Registry.
- MJ Rametta is a salaried employee of Bayer HealthCare.

AUTHOR CONTRIBUTIONS

- PK Coyle: Interpreted data and actively contributed to the writing and reviewing of the submitted manuscript. Member of the data safety monitoring board
- SM Sinclair-~~Roberts~~: Interpreted data and actively contributed to the writing and reviewing of the submitted manuscript. Member of the data safety monitoring board
- AE Scheuerle: Interpreted data and actively contributed to the writing and reviewing of the submitted manuscript. Member of the data safety monitoring board
- JM Thorp: Interpreted data and actively contributed to the writing and reviewing of the submitted manuscript. Member of the data safety monitoring board
- J Albano: Provided oversight for the conduct of the study, including the statistical analysis, interpreted data, and actively contributed to the writing and reviewing of the manuscript
- MJ Rametta: Interpreted data and actively contributed to the writing and reviewing of the submitted manuscript. Sponsor's responsible clinician for registry

This study was funded by Bayer HealthCare Pharmaceuticals, Inc.

References

- 1
- 2
- 3 1. Bennett KA. Pregnancy and multiple sclerosis. *Clin Obstet Gynecol*.
4 2005;48(1):38-47.
- 5
- 6
- 7 2. Vlahiotis A, Sedjo R, Cox ER, Burroughs TE, Rauchway A, Lich R. Gender
8 differences in self-reported symptom awareness and perceived ability to manage
9 therapy with disease-modifying medication among commercially insured multiple
10 sclerosis patients. *J Manag Care Pharm*. 2010;16(3):206-216.
- 11
- 12
- 13 3. Compston A, Coles A. Multiple sclerosis. *Lancet*. 2002;359(9313):1221-1231.
- 14
- 15 4. Coyle PK, Christie S, Fodor P, et al. Multiple sclerosis gender issues: clinical
16 practices of women neurologists. *Mult Scler*. 2004;10(5):582-588.
- 17
- 18 5. Betaseron [package insert]. Montville, NJ: Bayer HealthCare Pharmaceuticals;
19 2010.
- 20
- 21 6. Tysabri [package insert]. Cambridge, MA: Biogen Idec Inc; 2012.
- 22
- 23 7. Avonex [package insert]. Cambridge, MA: Biogen Idec Inc; 2012.
- 24
- 25 8. Gilenya [package insert]. East Hanover, NJ: Novartis Pharmaceuticals
26 Corporation; 2012.
- 27
- 28 9. Copaxone [package insert]. Kansas City, MO: TEVA Neuroscience; 2012.
- 29
- 30 10. Mitoxantrone [package insert]. Kansas City, MO: TEVA Neurosciences; 2012.
- 31
- 32 11. Rebif [package insert]. Rockland, MA: EMD Serono; 2012.
- 33
- 34 12. Aubagio [package insert]. Cambridge, MA: Genzyme Corporation; 2012.
- 35
- 36 13. Tecfidera [package insert]. Cambridge, MA: Biogen Idec Inc; 2013.
- 37
- 38 14. Extavia [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation;
39 2012.
- 40
- 41 15. US Department of Health and Human Services OoWH. Pregnancy and Medicines.
42 Available at [http://www.womenshealth.gov/publications/our-publications/fact-](http://www.womenshealth.gov/publications/our-publications/fact-sheet/pregnancy-medicines.pdf)
43 [sheet/pregnancy-medicines.pdf](http://www.womenshealth.gov/publications/our-publications/fact-sheet/pregnancy-medicines.pdf). Accessed December 21, 2012.
- 44
- 45 16. Covington D, Roberts S, McKain L. Impact of prenatal testing on birth defect
46 prevalence in pregnancy exposure registries. *Pharmacoepidemiol Drug Saf*.
47 2008;17(Supplement 1):S13.
- 48
- 49 17. US Food and Drug Administration. Guidance for industry establishing pregnancy
50 exposure registries. Available at
51 [http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/WomensHealthRe-](http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/WomensHealthResearch/UCM133332.pdf)
52 [search/UCM133332.pdf](http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/WomensHealthResearch/UCM133332.pdf). Accessed February 2014.
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

18. Scheuerle A, Tilson H. Birth defect classification by organ system: a novel approach to heighten teratogenic signalling in a pregnancy registry. *Pharmacoepidemiol Drug Saf.* 2002;11(6):465-475.
19. Jones RK, Kost K. Underreporting of induced and spontaneous abortion in the United States: an analysis of the 2002 National Survey of Family Growth. *Stud Fam Plann.* 2007;38(3):187-197.
20. Correa A, Cragan J, Kucik J. Metropolitan Atlanta Congenital Defects Program 40th anniversary edition surveillance report: reporting birth defects surveillance data. *Birth Defects Research (Part A).* 2007;79:65-93.
21. Correa A, Cragan J, Kucik J, et al. Errata. *Birth Defects Research (Part A).* 2008;82(1):41-62.
22. U.S.Census Bureau. Overview of race and Hispanic origin: 2010. <http://www.census.gov/prod/cen2010/briefs/c2010br-02.pdf>. Accessed April 2013.
23. Jones CA, Pohar SL, Warren S, Turpin KV, Warren KG. The burden of multiple sclerosis: a community health survey. *Health Qual Life Outcomes.* 2008;6:1.
24. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, et al. CDC growth charts: United States. *Adv Data.* 2000;(314):1-27.
25. Lu E, Wang BW, Guimond C, Synnes A, Sadovnick D, Tremlett H. Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review. *Neurology.* 2012;79(11):1130-1135.
26. Amato MP, Portaccio E, Ghezzi A, et al. Pregnancy and fetal outcomes after interferon-beta exposure in multiple sclerosis. *Neurology.* 2010;75(20):1794-1802.
27. Boskovic R, Wide R, Wolpin J, Bauer DJ, Koren G. The reproductive effects of beta interferon therapy in pregnancy: a longitudinal cohort. *Neurology.* 2005;65(6):807-811.
28. Weber-Schoendorfer C, Schaefer C. Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study. *Mult Scler.* 2009;15(9):1037-1042.
29. Patti F, Cavallaro T, Lo FS, et al. Is in utero early-exposure to interferon beta a risk factor for pregnancy outcomes in multiple sclerosis? *J Neurol.* 2008;255(8):1250-1253.
30. Hellwig K, Haghikia A, Rockhoff M, Gold R. Multiple sclerosis and pregnancy: experience from a nationwide database in Germany. *Ther Adv Neurol Disord.* 2012;5(5):247-253.

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
31. Tomczyk S, Richman S, Wallace K, Liu S, Sperling B. Final results from the AVONEX (intramuscular-beta-1a) pregnancy exposure registry. Presented at the Annual Meeting of the European Society for Research and Treatment in Multiple Sclerosis. Lyon, France. October 10-13. 2012.
32. Tomczyk S, Sperling B. Post-marketing pregnancy outcomes in patients exposed to intramuscular-interferon-beta-1a. Presented at the Annual Meeting of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France. October 10-13. 2012.
33. Hughes S, Spelman T, Gray O, et al. Exposure to interferon-beta therapy in early pregnancy: a literature review of pregnancy outcomes in women with multiple sclerosis. *J Neurol Neurosurg Psychiatry*. 2012;83:Supple 2 A17.

STROBE Statement—checklist of items that should be included in reports of observational studies

| | Item No | Recommendation |
|------------------------------|---------|---|
| Title and abstract | 1 | (a) Indicate the study's design with a commonly used term in the title or the abstract Title includes the word "registry." (b) Provide in the abstract an informative and balanced summary of what was done and what was found - complete |
| Introduction | | |
| Background/rationale | 2 | Explain the scientific background and rationale for the investigation being reported Paragraph 1 on page 4 |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses Paragraph on page 5 |
| Methods | | |
| Study design | 4 | Present key elements of study design early in the paper Pages 6-8 |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection Paragraph 2 on page 6; paragraph 1 on page 9 |
| Participants | 6 | (a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up Paragraph 2-3, page 6 |
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable Paragraph 2, page 6; paragraph 1-2 on page 7 |
| Data sources/ measurement | 8* | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group Paragraph 2, page 6 |
| Bias | 9 | Describe any efforts to address potential sources of bias Paragraph 3, page 7 |
| Study size | 10 | Explain how the study size was arrived at Paragraph 2, page 9 |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why Paragraph 2, page 8 |
| Statistical methods | 12 | (a) Describe all statistical methods, including those used to control for confounding Paragraph 2, page 8 (b) Describe any methods used to examine subgroups and interactions Paragraph 2, page 8 |

Continued on next page

Results

| | | |
|------------------|-----|--|
| Participants | 13* | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed Paragraph 2, page 9 |
| | | (b) Give reasons for non-participation at each stage Paragraph 2, page 9 |
| | | (c) Consider use of a flow diagram |
| Descriptive data | 14* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders Paragraph 2, page 9; paragraph 1 page 10; Table 2 |
| | | (b) Indicate number of participants with missing data for each variable of interest Paragraph 2, page 9; Table 2 |
| Outcome data | 15* | <i>Cohort study</i> —Report numbers of outcome events or summary measures over time Pages 11-15 |
| Main results | 16 | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included - NA Paragraph 2, page 9 |
| | | (b) Report category boundaries when continuous variables were categorized - NA Paragraph 2, page 9 |
| | | (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period - NA Paragraph 2, page 9 |
| Other analyses | 17 | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses Paragraph 1, page 16 |

Discussion

| | | |
|------------------|----|--|
| Key results | 18 | Summarise key results with reference to study objectives Paragraph 2, page 16 |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias Paragraph 1, page 16; paragraph 1, page 18 |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence Paragraph 2, page 18 |
| Generalisability | 21 | Discuss the generalisability (external validity) of the study results Paragraph 2, page 18 |

Other information

| | | |
|---------|----|--|
| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based Paragraph 1, page 8 |
|---------|----|--|

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

1
2 **Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and
3 published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely
4 available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at
5 <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is
6 available at www.strobe-statement.org.
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

BMJ Open

Final results from the Betaseron® (interferon beta-1b) Pregnancy Registry: a prospective observational study of birth defects and pregnancy-related adverse events

| | |
|---------------------------------|---|
| Journal: | <i>BMJ Open</i> |
| Manuscript ID: | bmjopen-2013-004536.R2 |
| Article Type: | Research |
| Date Submitted by the Author: | 04-Apr-2014 |
| Complete List of Authors: | Coyle, Patricia; Stony Brook University and MS Comprehensive Care Center, Roberts, Susan; University of North Carolina Wilmington, Clinical Research Program Scheuerle, Angela; Tesseræ Genetics, Medical Genetics Thorp, John; University of North Carolina Schools of Medicine and Public Health, Department of Obstetrics and Gynecology Albano, Jessica; INC Research LLC, Post Approval and Strategic Services Rametta, Mark; Bayer HealthCare Pharmaceuticals, |
| Primary Subject Heading: | Neurology |
| Secondary Subject Heading: | Neurology, Obstetrics and gynaecology, Pharmacology and therapeutics, Reproductive medicine |
| Keywords: | Multiple sclerosis < NEUROLOGY, interferon beta-1b, pediatrics, pregnancy, congenital abnormalities |
| | |

SCHOLARONE™
Manuscripts

1
2
3 **Final results from the Betaseron® (interferon beta-1b) Pregnancy Registry: a**
4 **prospective observational study of birth defects and pregnancy-related adverse**
5 **events**
6
7

8
9 **Authors:** PK Coyle, MD;¹ SM Sinclair, PhD, MPH, RN;² AE Scheuerle, MD;³ JM Thorp
10 Jr, MD;⁴ JD Albano, PhD, MPH;⁵ MJ Rametta, DO⁶
11
12

13
14 ¹Stony Brook University Department of Neurology and MS Comprehensive Care Center,
15 Stony Brook, NY
16

17 ²University of North Carolina Wilmington, Clinical Research Program, Wilmington, NC
18

19 ³Tesserae Genetics, Medical Genetics, Dallas, TX
20

21 ⁴University of North Carolina Schools of Medicine and Public Health, Department of
22 Obstetrics and Gynecology, Chapel Hill, NC
23

24 ⁵INC Research LLC, Post Approval and Strategic Services, Raleigh, NC
25

26 ⁶Bayer HealthCare Pharmaceuticals, US Medical Affairs, Neurology, Whippany, NJ
27
28
29

30 **Correspondence to:**

31 Name: Patricia Coyle
32

33 Affiliation: Stony Brook University and MS Comprehensive Care Center
34

35 Address: HSC T12-020; SUNY at Stony Brook, Stony Brook, NY 11794-8121
36

37 Telephone number: 631-444-8188
38

39 Fax number: 631-444-1474
40

41 Email address: patricia.coyle@stonybrookmedicine.edu
42
43

44 **Search terms:** multiple sclerosis, interferon beta-1b, pediatrics, pregnancy, congenital
45 abnormalities
46
47

48
49 **Word count:** 2,784 words
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objectives: Women with multiple sclerosis are often diagnosed and treated during their reproductive years. Limited data are available on the safety of treatment during pregnancy. The Betaseron® Pregnancy Registry prospectively monitored women exposed to interferon beta-1b (IFNB-1b) during pregnancy to estimate the rates of birth defects, spontaneous abortions (SABs), and other negative outcomes in this population.

Design: From 2006-2011, this observational registry enrolled women exposed prior to conception or during pregnancy (but prior to or without abnormalities on prenatal screening). Follow-up continued from enrollment through the 4-month pediatric visit.

Setting: Patients in the United States who met these criteria were enrolled in the registry.

Results: The registry enrolled 99 pregnant women; 3 were lost to follow up. The earliest exposure to IFNB-1b occurred during the first trimester for 95 pregnancies and the third trimester for 1 pregnancy. There were 99 birth outcomes (3 twins), including 86 (86.9%) live births, 11 (11.1%) SABs, and 2 (2.0%) stillbirths. Birth defects were reported in 5 (5.1%) cases. Rates of birth defects and SAB were not significantly different from population comparators. No developmental concerns were identified at the 4 month pediatric visit.

Conclusions: The small sample size limits the ability to draw definitive conclusions; however, there was no pattern to suggest increased negative outcomes with IFNB-1b.

ARTICLE SUMMARY

Strengths and limitations of this study

- The Betaseron Pregnancy Registry contains the largest sample of interferon beta-1b-exposed pregnancies collected to date
- The relatively small sample size limits the ability to draw definitive conclusions; however, there was no pattern to suggest increased negative outcomes with interferon beta-1b
- Limitations of the Betaseron Pregnancy Registry include the potential for underreporting or differential reporting of outcomes due to the exclusion of retrospective patients and the voluntary nature of participation
- Birth defect ascertainment was limited to data obtained from reporting health care providers; infants were not examined directly as part of the registry
- Data on infant outcomes were only collected for up to 4 months, reducing the ability of the registry to measure developmental progress, defects diagnosed beyond 4 months of age, and resolution of suspected defects reported in early infancy

INTRODUCTION

Multiple sclerosis (MS) is a chronic demyelinating and neurodegenerative disorder that affects over 400,000 people in the United States.^{1,2} MS is much more common in women than men, and diagnosis frequently occurs when patients are in their 20s and 30s.^{3,4} Consequently, women of child-bearing age constitute a considerable portion of all patients with MS. Furthermore, up to 10% have disease onset during pregnancy.¹

The approved disease-modifying treatments (DMTs) for patients with MS have been given pregnancy category ratings of B, C, D, or X by the US Food and Drug Administration based on clinical experience and/or preclinical data (see Table 1 for pregnancy categorizations of currently-approved DMTs and a definition of different pregnancy classifications).⁵⁻¹⁴ The safety of these agents during pregnancy is a major concern given the patient profile outlined above. However, data on pregnancy outcomes in DMT-exposed patients is limited. Among the beta interferons, this is particularly true for interferon beta-1b (Betaseron[®]/Betaferon[®]; Bayer HealthCare Pharmaceuticals; Whippany, NJ).

Table 1. Pregnancy classifications of disease modifying treatments (DMTs) approved for use by patients with MS.

| Disease-modifying therapy | Pregnancy category |
|---|--------------------|
| Glatiramer acetate (Copaxone [®]) ⁹ | B |
| Interferon beta-1b (Betaseron [®] /Betaferon [®] ; Extavia [®]) ^{5,14} | C |
| Intramuscular interferon beta-1a (Avonex [®]) ⁷ | C |

| | |
|--|---|
| Subcutaneous interferon beta-1a (Rebif [®]) ¹¹ | C |
| Fingolimod (Gilenya [®]) ⁸ | C |
| Dimethyl fumarate (Tecfidera [®]) ¹³ | C |
| Natalizumab (Tysabri [®]) ⁶ | C |
| Mitoxantrone ^{6,10} | D |
| Teriflunomide (Aubagio [®]) ^{6,10,12} | X |
| FDA pregnancy categories ¹⁵ <ul style="list-style-type: none"> • Category A: No evidence of adverse effects in studies of pregnant humans • Category B: No studies from humans, but no evidence of adverse effects in studies of pregnant animals; or negative effects observed in animal models but no evidence of adverse effects in humans • Category C: Insufficient evidence from human studies, but research with pregnant animals identified some medication-related negative outcomes; in some situations, the medication may be more beneficial than harmful • Category D: Medication-related negative outcomes in human studies but medication may be needed in some situations • Category X: Medication-related negative outcomes in human or animal studies; there are no situations in which the medicine should be used | |

No teratogenic effects were seen in studies of pregnant rhesus monkeys exposed to interferon beta-1b. However, dose-related abortifacient activity was seen at doses from 0.028 mg/kg/d to 0.42 mg/kg/d, which is 2.8 to 4.0 times the recommended human dose based on surface area comparison.⁵ Although data on human exposure during pregnancy are limited, patients are advised to discontinue treatment with interferon beta-1b if they become pregnant or plan to become pregnant.⁵ The goal of the

1
2
3 Betaseron Pregnancy Registry was to compare pregnancy outcomes in women
4
5 exposed to interferon beta-1b at conception or during pregnancy relative to general
6
7 population comparators. This is the largest observational study reported to date for
8
9 interferon beta-1b.
10
11
12
13
14
15
16

17 **METHODS**

18 **Population and outcome measures**

19
20
21 The Betaseron Pregnancy Registry was a voluntary, prospective, observational,
22
23 exposure-registration and follow-up study. Women with an existing pregnancy who had
24
25 been exposed to interferon beta-1b at any time after the first day of the last menstrual
26
27 period (LMP), or during pregnancy but before any prenatal screening (eg, ultrasound,
28
29 amniocentesis), were prospectively enrolled in the registry. Women with similar
30
31 exposure who had undergone some prenatal testing and were without abnormal
32
33 findings suggestive of fetal abnormalities were also enrolled. Given the widespread use
34
35 of early prenatal testing, restricting enrollment to women without prenatal testing would
36
37 have dramatically reduced the available population, hindering the success of the
38
39 registry.^{16,17} Because retrospective cases (ie, pregnancies submitted after the birth of
40
41 the infant or after evidence suggestive of an abnormality on prenatal tests) can be
42
43 biased toward reporting of unusual or severe outcomes, these cases and those in which
44
45 an abnormality was identified prior to registry contact were excluded.
46
47
48
49
50
51
52
53

54
55 The primary outcome measure was the rate of major congenital malformations in infants
56
57 exposed to interferon beta-1b during gestation, defined as any time after the first day of
58
59
60

1
2
3 the mother's LMP. Secondary outcome measures included the prevalence of
4
5 spontaneous abortion and other negative pregnancy outcomes in exposed women.
6
7
8 Prevalence of elective abortion, stillbirth, ectopic pregnancy, neonatal death, and
9
10 maternal death was assessed. Reporting was conducted by health care providers
11
12 (HCPs), patients, or representatives of the study sponsor. Maternal follow-up lasted
13
14 from enrollment through pregnancy outcome. Infant follow-up continued through the 4-
15
16 month pediatric visit in most cases.
17
18

19
20
21 Pregnancy outcomes were classified as live birth, spontaneous abortion, elective
22
23 abortion, or fetal death/stillbirth. A live birth was defined as any delivery resulting in a
24
25 viable neonate ≥ 24 weeks of gestation. The spontaneous loss of a fetus at < 20 weeks
26
27 of gestation was classified as a spontaneous abortion. Any fetus delivered dead ≥ 20
28
29 weeks of gestation, or weighing ≥ 500 g regardless of gestational age, was classified as
30
31 a stillbirth. Fetal death occurring > 20 weeks but < 28 weeks was classified as early fetal
32
33 loss while death occurring ≥ 28 weeks was considered late fetal loss. Elective abortions
34
35 encompassed any induced or voluntary ending of the pregnancy. Other pregnancy
36
37 outcomes included ectopic pregnancies, maternal death, and neonatal death. Infant size
38
39 was classified as "small," "appropriate," or "large" for gestational age based on HCP
40
41 assessment.
42
43
44
45

46
47 Birth defects were defined as any significant structural or chromosomal defect
48
49 diagnosed with signs/symptoms using the Metropolitan Atlanta Congenital Defects
50
51 Program (MACDP) classification of birth defects, or any case with 2 or more secondary
52
53 or "conditional" abnormalities that would not have been classified as primary birth
54
55 defects by MACDP. Conditional abnormalities, some of which were also referred to as
56
57
58
59
60

1
2
3 “minor birth defects”, were included if present in a cluster of 2 or more to increase the
4 sensitivity of monitoring and to avoid missing a potential signal. Birth defects were
5 coded using an organ system classification to increase the possibility of detecting a
6 potential signal by grouping together similar defects or defects with similar etiology.¹⁸ All
7 cases were coded in accordance with both the MACDP code book and the organ
8 system classification by an expert in dysmorphology (AES) who evaluated the potential
9 temporal relationship between the exposure to interferon beta-1b and the etiology of the
10 defect, considering other potential confounders (eg, exposure to other therapies
11 received during the pregnancy, maternal or paternal history of defects, underlying
12 disease).¹⁸ Further follow-up for birth defect cases was conducted if additional
13 information was needed by the dysmorphologist or the data safety monitoring board
14 (DSMB). Defects were classified as “Defect with a known cause, temporality may be
15 irrelevant;” “No temporal association;” or “Unable to assess temporality.” Available data
16 for each defect case were reviewed individually for potential confounders and relevant
17 information was evaluated and recorded.

18
19
20 Conduct of the registry was overseen by an independent DSMB. The Western
21 Institutional Review Board (WIRB) reviewed and approved the protocol, which included
22 a waiver of documentation of informed consent. The Betaseron Pregnancy Registry was
23 listed in the public trials registry (www.clinicaltrials.gov) under NCT00317564.

24 25 26 **Statistical procedures**

27
28
29 Analyses were conducted on all prospective evaluable cases (ie, enrolled pregnancies,
30 not lost to follow-up, with known outcome and birth defect status). The birth defect rate
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 was calculated by dividing the number of cases with birth defects among all live births
4 and fetal losses >20 weeks gestation (numerator) by the number of live births
5 (denominator). This approach increased the sensitivity of monitoring and may have
6 overestimated the true rate; however it erred on the side of caution. Since the presence
7 or absence of birth defects is difficult to ascertain among fetal losses, including fetal
8 losses in the denominator would have biased the birth defect rate downwards. Ninety-
9 five percent exact confidence intervals (CI) were calculated for birth defect rate and
10 other point estimates. Outcome data were stratified by the earliest trimester of exposure
11 to interferon beta-1b.
12
13
14
15
16
17
18
19
20
21
22
23
24

25 Population-based external comparator groups were used to evaluate the rates of
26 spontaneous abortion and birth defects in the registry. Risk of spontaneous abortions
27 was compared with estimates for the general population of the United States from the
28 National Survey of Family Growth (NSFG), which was conducted by the National Center
29 for Health Statistics,¹⁹ using Fisher's exact test based on binomial distribution for
30 exposures. Risk of birth defects was compared with that reported by the MACDP.^{20,21}
31 This population-based birth defect surveillance system includes all infants born in the
32 metropolitan area of Atlanta, Georgia. From 1999 to 2003, the MACDP estimated the
33 population birth defect rate to be 2.78 birth defects per 100 live births in its
34 database.^{20,21}
35
36
37
38
39
40
41
42
43
44
45
46
47
48

49 When the Registry was designed and launched, it aimed to enroll approximately 420
50 pregnant women to reach the goal of 210 live births to evaluate the primary endpoint
51 (risk of birth defects). This sample size was estimated to be sufficient to rule out a 2.2-
52 fold increase in birth defects compared to the MACDP rate of 2.78^{20,21} with 80% power
53
54
55
56
57
58
59
60

1
2
3 (assuming a 5% level of significance). The sample size goal of 420 pregnancies was
4
5 expected to result in only 210 live births because of losses to follow up, enrollment
6
7 failures, and a live birth rate of 62%.¹⁷. After approximately 5 years of operation,
8
9 Registry enrollment resulted in only 99 live births.
10
11

12 13 **Role of the funding source**

14
15
16
17 The study was jointly designed by members of the DSMB and the study sponsor. The
18
19 authors, which included both the DSMB and representatives of the sponsor, had access
20
21 to all the data, participated in analysis and interpretation, and were members of the
22
23 publication committee. The decision to submit the article for publication was made
24
25 jointly by the members of the steering committee and the sponsor.
26
27
28
29
30
31
32

33 **RESULTS**

34 35 **Patient disposition**

36
37
38
39 Between April 24, 2006 and July 31, 2011, 99 pregnant women were prospectively
40
41 enrolled in the Betaseron Pregnancy Registry. Follow-up of pregnant women and their
42
43 live-born infants continued through July 16, 2012. Pregnancy outcomes were reported
44
45 for 96 exposed pregnancies, with 3 pregnancies lost to follow-up (Table 2). Initial
46
47 exposure to interferon beta-1b occurred in the first trimester for 95 patients, and in the
48
49 third trimester for 1 patient. Seventy-four patients had pediatric follow up. For the
50
51 remaining 22 patients, follow-up continued only until birth. Prenatal testing prior to
52
53 enrollment was reported in 33 cases (34.4%).
54
55
56
57
58
59
60

Table 2. Maternal demographics.

| | Analysis population (N=96) |
|--|---------------------------------------|
| Age at enrollment (years) | |
| n | 95 ^a |
| Mean (SD) | 30.9 (5.29) |
| Median (range) | 31.0 (19-44) |
| Age category, n (%) | |
| ≤19 years | 1 (1.0) |
| 20-34 years | 69 (71.9) |
| ≥35 years | 25 (26.0) |
| Missing | 1 (1.0) |
| Race/ethnicity, n (%) | |
| White | 62 (64.6) |
| Black | 25 (26.0) |
| Hispanic | 2 (2.1) |
| Asian | 0 (0) |
| Other | 6 (6.3) |
| Missing | 1 (1.0) |
| MS duration at enrollment, n (%) | |
| <1 year | 23 (24.0) |
| 1-5 years | 51 (53.1) |
| 6-10 years | 11 (11.5) |
| >10 years | 6 (6.3) |
| Missing | 5 (5.2) |
| Earliest trimester of exposure, ^b n (%) | |
| First | 95 (99.0) |
| Second | 0 (0) |

| | |
|---------------------------------------|-----------|
| Third | 1 (1.0) |
| Prenatal tests, n (%) | |
| Prenatal test(s) after enrollment | 53 (55.2) |
| Prenatal test(s) prior to enrollment | 33 (34.4) |
| Date of prenatal test(s) not provided | 1 (1.0) |
| No prenatal tests | 7 (7.3) |
| Missing/unknown | 2 (2.1) |

^a Age data were missing for 1 case.

^b First trimester exposure was initial exposure occurring from the first day of the LMP through 13 weeks gestation; third trimester exposure was initial exposure occurring in the 28th week through the end of the pregnancy.

The majority of the sample was white (62 patients [64.6%]); 25 patients (26.0%) were black. In addition, 2 patients (2.1%) were Hispanic while 6 patients were of other races/ethnicities (6.3%) and race/ethnicity data were missing for 1 patient (1.0%). Note that the distribution of race/ethnicity in the Betaseron Pregnancy Registry was different from population norms in the United States (72.4% white, 12.6% black, 16.3% Hispanic).²²

Pregnancy outcomes

From the 96 evaluable pregnancies, there was a total of 99 birth outcomes available, including 3 sets of twins. These outcomes included 86 live births, 2 stillbirths, and 11 spontaneous abortions (Table 3). Both stillbirths occurred in black women with a history of prior spontaneous abortion and other comorbidities that may have affected birth outcomes. The first case, ending in stillbirth, reported hypertension, obesity (post gastric bypass), and oligohydramnios. The second reported antiphospholipid antibody

1
2
3 syndrome, maternal human papillomavirus infection, early rupture of membranes
4 attributed to vaginal bacterial infection, and preterm labor and delivery attributed to
5 incompetent cervix. The prevalence of spontaneous abortion in the Betaseron
6 Pregnancy Registry (11.5% [95% CI 5.9–19.6]) was not significantly different from the
7 16% estimate for the general population of the United States based on NSFG data
8 (relative risk 0.7 [95% CI 0.4–1.2], P=.86, Fisher's exact test based on binomial
9 distribution for exposures).
10
11
12
13
14
15
16
17
18
19
20
21
22

23 **Table 3.** Pregnancy outcomes in the Betaseron Pregnancy Registry.

| Outcomes, n (% , 95% CI) | Interferon beta-1b– exposed pregnancies | Relative risk (RR) (95% CI) |
|-----------------------------------|--|---|
| Live births (N=96) | 83 (86.4%) | - |
| Birth defects (N=86) ^a | 5 (5.8%, 1.9–13.0) | RR (95% CI) 2.1 (0.9–4.9), P=0.092 ^b |
| Spontaneous abortions (N=96) | 11 (11.5%, 5.9–19.6) | RR (95% CI) 0.7 (0.4–1.2) P=0.8603 ^c |
| Stillbirth (N=96) | 2 (2.1) | - |
| Maternal deaths | 0 (0) | - |
| Infant deaths | 0 (0) | - |
| Ectopic pregnancies | 0 (0) | - |

24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

^a Excludes spontaneous and elective abortions <20 weeks gestation with reported birth defects per MACDP convention. The denominator is restricted to live births.

^b Relative risk compared with 2.78% reported by MACDP; Fisher's exact test based on binomial distribution for exposures.^{20,21}

^c Relative risk compared with 16.0% rate of SAB reported by NSFG; Fisher's exact test.²³

1
2
3 Infant assessments were made at birth for 86 babies, up to 3 months of age for 74
4 babies, and at 4 months for 59 babies (Table 4). HCPs assessed infant size as
5 appropriate for gestational age at birth for 67 cases (77.9%). Four-month follow-up did
6 not identify any consistent pattern of developmental abnormalities. Birth defects were
7 identified in 5 cases (Table 5), resulting in a relative risk of 2.1 (95% CI 0.9–4.9). The
8 reported birth defects occurred in several different organ systems, including the
9 musculoskeletal, cardiovascular, and circulatory systems, with no pattern to the organ
10 systems affected. For all cases reporting birth defects, the earliest exposure to
11 interferon beta-1b 250 micrograms dosed every other day occurred during the first
12 trimester of gestation. No birth defects were reported among the spontaneous
13 pregnancy losses or stillbirths. The birth defect rate estimated by the Betaseron
14 Pregnancy Registry (5.8% [95% CI 1.9–13.0]) was not significantly different from that
15 reported by MACDP (2.78%, $P=.092$, Fisher's exact test). The relatively wide
16 confidence intervals, which include the MACDP rate, reflect the small sample size and
17 suggest no difference between the birth defect rate from the Betaseron Pregnancy
18 Registry and the MACDP.

19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45 **Table 4.** Infant assessments at birth and at 4 months.

| | At birth | At 4-month follow-up | Approximate median in US population at birth ²⁴ |
|-------------------|-----------|----------------------|--|
| Number of infants | 86 | 59 | |
| Sex, n (%) | | | |
| Female | 40 (46.5) | 26 (44.1) | |

| | | | |
|--|--------------|---------------|-----------|
| Male | 46 (53.5) | 33 (55.9) | |
| Infant weight, g | | | |
| Median | 3346.8 | 6747.0 | 3200-3600 |
| Range | 470.0-4593.0 | 4763.0-8902.0 | |
| Infant size, n (%) ^a | | | |
| Small | 7 (8.1) | 3 (5.1) | |
| Appropriate | 67 (77.9) | 48 (81.4) | |
| Large | 7 (8.1) | 6 (10.2) | |
| Missing | 5 (5.8) | 2 (3.4) | |
| Infant length (cm) | | | |
| Median | 50.8 | 63.5 | 49-50 |
| Range | 30.5-55.9 | 53.3-69.3 | |
| Infant head circumference (cm) | | | |
| Median | 34.3 | 41.9 | 34.8-35.8 |
| Range | 29.5-38.1 | 37.0-44.5 | |
| Gestational age at birth (weeks) | | | |
| Median | 39.0 | NA | |
| Range | 24.0-41.0 | NA | |
| Gestational age at birth, n (%) ^{b,c} | | | |
| Preterm | 8 (10.0) | NA | 9.9% |
| Term | 72 (90.0) | NA | |

^a Infant size relative to gestational age at birth and age at 4 months (± 4 weeks), respectively.

^b Gestational age at birth calculated as $[(280 - (\text{corrected estimated due date} - \text{outcome date})) / 7]$; estimated due date (EDD) was used when corrected EDD was not available. Preterm births were defined as any baby born before the end of the 36th gestational week and term births were defined as those born after ≥ 37 weeks, 0 days gestation.²⁵

^c Among singleton live births; excludes 3 twin pregnancies (6 live births) with outcomes at 24 weeks, 5 days; 36 weeks, 3 days; and 36 weeks, 5 days.

Table 5. Summary of birth defect cases

| Case | Description of the reported birth defects ^a | Organ system | Temporality assessment |
|------|---|---|--|
| 1 | Live infant, male, 34 weeks gestation 1. Trisomy 21 (Down syndrome) ^b | 1. Chromosome anomaly | 1. Defect with known cause, temporality may be irrelevant |
| 2 | Live infant, male, 40 weeks gestation 1. Hemangioma (capillary hemangioma parietal area and left 3rd toe) | 1. Circulatory system | 1. Unable to assess temporality |
| 3 | Live infant, female, 39 weeks gestation 1. Hip dysplasia (defect) 2. Patent foramen ovale (conditional defect) 3. Patent ductus arteriosus (conditional defect) 4. Ventriculoseptal defect (defect) | 1. Other musculoskeletal defects 2. Heart 3. Circulatory system 4. Heart | 1. Unable to assess temporality 2. Defect with known cause, temporality may be irrelevant 3. Defect with known cause, temporality may be irrelevant 4. Defect with known cause, temporality may be irrelevant |
| 4 | Live infant, male, 36 weeks gestation 1. Abnormal shape of the head without craniosynostosis | 1. Musculoskeletal defects | 1. No temporal association |
| 5 | Live infant, male, 38 weeks gestation 1. Polydactyly | 1. Limb reduction/addition defects | 1. No temporal association |

^a Gestational age data are birth ages, not age at exposure.

^b The mother of this infant was older than 35 years of age.

1
2
3 Because of the relatively high percentage of black patients in the Betaseron Pregnancy
4 Registry, a subanalysis of pregnancy outcome data was conducted to compare black
5 and non-black patients. No significant differences were seen between these two
6 populations in the rates of birth defects or rates of spontaneous abortion. However,
7 small sample sizes in this subanalysis limit the conclusions that can be drawn from
8 these data.
9
10
11
12
13
14
15
16
17
18
19
20
21

22 **DISCUSSION**

23
24 This Betaseron Pregnancy Registry reported 99 outcomes in 96 evaluable pregnancies
25 (including 3 twin pregnancies), consisting of 86 live births, 2 stillbirths, and 11
26 spontaneous abortions. There were 5 cases with birth defects. Among these 5 cases
27 were a variety of birth defects which were not clustered around a single type of defect or
28 effected organ system. In addition, 2 of these cases had defects that were not
29 temporally related to interferon beta-1b exposure (ie, the timing of the exposure was not
30 consistent with the development of the defect) and 1 had a chromosomal abnormality
31 potentially related to advanced maternal age that was classified as having no temporal
32 association to exposure. This lack of a consistent pattern suggests that there was no
33 signal for birth defects due to interferon beta-1b exposure. The risk of spontaneous
34 abortion or birth defect was not significantly different from comparator populations. In
35 addition, no elective abortions or maternal deaths were observed and there were no
36 abnormalities in rate of prematurity or in birth weight/size. These data represent the
37 largest cohort of interferon beta-1b-exposed patients reported to date; however, the
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 sample size was still smaller than necessary to have sufficient statistical power to draw
4
5 definitive conclusions.
6
7

8
9 To date, several publications have discussed the results of exposure to interferon beta
10
11 formulations during pregnancy; however none have exclusively examined interferon
12
13 beta-1b exposure. A recent review of this literature suggested that beta interferons may
14
15 be associated with some negative outcomes,²⁶ a conclusion that contrasts with the
16
17 findings presented here. Three studies, also with small sample sizes, (N=88, N=69, and
18
19 N=23) found low birth weight in infants exposed to interferon beta formulations (either
20
21 interferon beta-1a or beta-1b) during gestation.²⁷⁻²⁹ Another study (N=14) found
22
23 evidence of prematurity with interferon beta exposure, but birth weight was not
24
25 significantly lower than unexposed comparators.³⁰ However, another study (N=63) did
26
27 not find evidence of low birth weight following interferon beta exposure.³¹ Other negative
28
29 pregnancy outcomes, including a higher rate of spontaneous abortion and shorter mean
30
31 birth length, have also been associated with exposure to interferon beta
32
33 formulations.^{27,28}
34
35
36
37
38
39

40
41 In contrast, the Betaseron Pregnancy Registry did not find any patterns to suggest
42
43 negative pregnancy outcomes associated with interferon beta-1b exposure. It should be
44
45 noted that the 5 aforementioned studies combined subjects exposed to either interferon
46
47 beta-1a or beta-1b into a single group.²⁷⁻³¹ Two of these studies did not provide
48
49 separate numbers of interferon beta-1a and beta-1b-exposed patients.^{27,29} In the 3
50
51 studies that divided exposure groups into interferon beta-1a and beta-1b, patients with
52
53 interferon beta-1b monotherapy exposure numbered only 10–21^{28,30,31}, thereby limiting
54
55 the statistical power to draw conclusions about the effects of interferon beta-1b on
56
57
58
59
60

1
2
3 pregnancy outcomes. The Betaseron Pregnancy Registry data reported here have the
4
5 advantage of a much larger sample size (99 outcomes), albeit much lower than planned
6
7 when the registry was designed.
8
9

10
11 The Betaseron Pregnancy Registry included pediatric follow-up, which has not been not
12
13 consistently reported in other studies: only 2 other studies have assessed pediatric
14
15 outcomes.^{27,30} The first (N=14) reported normal development of interferon beta-1a- or
16
17 beta-1b-exposed infants up to the 12-month milestones (walking and talking).³⁰ A later
18
19 study (N=88) found no developmental abnormalities in interferon beta-exposed infants
20
21 after 2.1 years of follow-up.²⁷ The Betaseron Pregnancy Registry's findings are
22
23 consistent with these previous reports and reinforce the hypothesis that there are no
24
25 obvious postnatal effects from in utero interferon beta-1b exposure.
26
27
28
29
30

31 The potential risks associated with interferon beta-1b exposure during pregnancy, which
32
33 were not found to be significantly different from comparator cohorts in this study, need
34
35 to be considered along with the risks for patients with MS who remain untreated during
36
37 pregnancy. Prior research suggested that MS itself was not associated with increased
38
39 risk for negative pregnancy outcomes.¹ However, risk for relapses is higher after
40
41 delivery, with 20%–40% of patients experiencing a clinical relapse or worsening of the
42
43 disease in the first 3 months postpartum.¹
44
45
46
47

48 The results reported here are similar to 2 recent presentations related to intramuscular
49
50 interferon beta-1a exposure during pregnancy. In the first, no pattern suggestive of
51
52 increased negative outcomes was found in 306 pregnancies in the Avonex Pregnancy
53
54 Exposure Registry.³² Similarly, post marketing surveillance (N=552) found the rate of
55
56
57
58
59
60

1
2
3 spontaneous abortion was consistent with the general population, with no evidence of
4 increased birth defect rates.³³ Together with the Betaseron Pregnancy Registry, the
5 preponderance of data suggest no pattern of increased negative outcomes for women
6 and infants exposed to interferon beta formulations during pregnancy, a finding that was
7 supported by a recent review of the literature related to interferon beta exposure during
8 pregnancy (N=1105).³⁴
9
10
11
12
13
14
15
16

17
18 This is also the first study to report on pregnancy exposure outcomes in black patients
19 with MS. No differences were noted based on race.
20
21
22

23
24 Limitations of the Betaseron Pregnancy Registry include the potential for underreporting
25 or differential reporting of outcomes due to the exclusion of retrospective patients.
26
27

28 However, it is important to note that data from these retrospective patients were
29 captured through post-marketing surveillance efforts. In addition, birth defect
30 ascertainment was limited to voluntary reports from health care providers (not unlike
31 population-based public health surveillance programs), which potentially limited the
32 level of detail needed to fully characterize a birth defect case and rule out missed or
33 misdiagnoses. Lastly, data on infant outcomes were only collected for up to 4 months,
34 reducing the ability of the registry to measure developmental progress.
35
36
37
38
39
40
41
42
43
44

45
46 Due to low sample size, definitive conclusions cannot be drawn from the Betaseron
47 Pregnancy Registry data. However, there was no pattern to suggest an increased risk of
48 birth defects in infants or an increased rate of spontaneous abortions in women after
49 exposure to interferon beta-1b during pregnancy. Infant assessments, such as birth
50 weight, birth length, and head circumference, also did not differ from population
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

estimates and the 4 month infant follow-up did not identify any developmental concerns.
Continued monitoring through routine post-marketing surveillance activities is
recommended.

For peer review only

ACKNOWLEDGMENTS

We are grateful to the patients and their healthcare providers for their contributions to the study. Additionally, we thank Robert C. Ristuccia, PhD (Precept Medical Communications), for assistance with preparation of the manuscript (funded by Bayer HealthCare Pharmaceuticals).

FUNDING

This study was funded by Bayer HealthCare Pharmaceuticals, Inc.

AUTHOR CONTRIBUTIONS

- PK Coyle: Interpreted data and actively contributed to the writing and reviewing of the submitted manuscript. Member of the data safety monitoring board
- SM Sinclair: Interpreted data and actively contributed to the writing and reviewing of the submitted manuscript. Member of the data safety monitoring board
- AE Scheuerle: Interpreted data and actively contributed to the writing and reviewing of the submitted manuscript. Member of the data safety monitoring board
- JM Thorp: Interpreted data and actively contributed to the writing and reviewing of the submitted manuscript. Member of the data safety monitoring board
- JD Albano: Provided oversight for the conduct of the study, including the statistical analysis, interpreted data, and actively contributed to the writing and reviewing of the manuscript
- MJ Rametta: Interpreted data and actively contributed to the writing and reviewing of the submitted manuscript. Sponsor's responsible clinician for registry

COMPETING INTERESTS

- PK Coyle has received compensation for consulting/educational activities from Aconda, Accordant, Bayer, Biogen Idec, Genentech/Roche, Genzyme/Sanofi Aventis, Merck-Serono, Mylan, Novartis, and Teva Neurosciences. She has received research funding from Actelion, Novartis, and Opexa.
- S Sinclair Roberts has received compensation for consulting activities from Bayer, Lilly, and INC Research.
- AE Scheuerle has received compensation for consulting activities from Abbott, Amylin, Bayer, Biogen Idec, INC Research, Genentech, Novartis, PPD, TAP Pharma, Roche, Teva, and UCB Pharma.
- JM Thorp has received compensation for consulting from Bayer, GlaxoSmithKline, and PPD.
- JD Albano is an employee of INC Research, the coordinating center for the Betaseron Pregnancy Registry.
- MJ Rametta is a salaried employee of Bayer HealthCare.

DATA SHARING STATEMENT

Some unpublished data remain in the final clinical study report. The data safety monitoring board of the registry (the authors of this paper) decided these data were not necessary for publication.

References

1. Bennett KA. Pregnancy and multiple sclerosis. *Clin Obstet Gynecol*. 2005;48(1):38-47.
2. Vlahiotis A, Sedjo R, Cox ER, et al. Gender differences in self-reported symptom awareness and perceived ability to manage therapy with disease-modifying medication among commercially insured multiple sclerosis patients. *J Manag Care Pharm*. 2010;16(3):206-216.
3. Compston A, Coles A. Multiple sclerosis. *Lancet*. 2002;359(9313):1221-1231.
4. Coyle PK, Christie S, Fodor P, et al. Multiple sclerosis gender issues: clinical practices of women neurologists. *Mult Scler*. 2004;10(5):582-588.
5. Betaseron [package insert]. Montville, NJ: Bayer HealthCare Pharmaceuticals; 2010.
6. Tysabri [package insert]. Cambridge, MA: Biogen Idec Inc; 2012.
7. Avonex [package insert]. Cambridge, MA: Biogen Idec Inc; 2012.
8. Gilenya [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2012.
9. Copaxone [package insert]. Kansas City, MO: TEVA Neuroscience; 2012.
10. Mitoxantrone [package insert]. Kansas City, MO: TEVA Neurosciences; 2012.
11. Rebif [package insert]. Rockland, MA: EMD Serono; 2012.
12. Aubagio [package insert]. Cambridge, MA: Genzyme Corporation; 2012.
13. Tecfidera [package insert]. Cambridge, MA: Biogen Idec Inc; 2013.
14. Extavia [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2012.
15. US Department of Health and Human Services OoWH. Pregnancy and Medicines. Available at <http://www.womenshealth.gov/publications/our-publications/fact-sheet/pregnancy-medicines.pdf>. Accessed December 21, 2012.
16. Covington D, Roberts S, McKain L. Impact of prenatal testing on birth defect prevalence in pregnancy exposure registries. *Pharmacoepidemiol Drug Saf*. 2008;17(Supplement 1):S13.
17. US Food and Drug Administration. Guidance for industry establishing pregnancy exposure registries. Available at

- 1
2
3 [http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/WomensHealthRe](http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/WomensHealthResearch/UCM133332.pdf)
4 [search/UCM133332.pdf](http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/WomensHealthRe). Accessed February 2014.
5
6
7 18. Scheuerle A, Tilson H. Birth defect classification by organ system: a novel
8 approach to heighten teratogenic signalling in a pregnancy registry.
9 *Pharmacoepidemiol Drug Saf.* 2002;11(6):465-475.
10
11 19. Jones RK, Kost K. Underreporting of induced and spontaneous abortion in the
12 United States: an analysis of the 2002 National Survey of Family Growth. *Stud*
13 *Fam Plann.* 2007;38(3):187-197.
14
15 20. Correa A, Cragan J, Kucik J. Metropolitan Atlanta Congenital Defects Program
16 40th anniversary edition surveillance report: reporting birth defects surveillance
17 data. *Birth Defects Research (Part A).* 2007;79:65-93.
18
19 21. Correa A, Cragan J, Kucik J, et al. Errata. *Birth Defects Research (Part A).*
20 2008;82(1):41-62.
21
22 22. U.S.Census Bureau. Overview of race and Hispanic origin: 2010.
23 <http://www.census.gov/prod/cen2010/briefs/c2010br-02.pdf>. Accessed April 2013.
24
25 23. Jones CA, Pohar SL, Warren S, et al. The burden of multiple sclerosis: a
26 community health survey. *Health Qual Life Outcomes.* 2008;6:1.
27
28 24. Kuczumski RJ, Ogden CL, Grummer-Strawn LM, et al. CDC growth charts: United
29 States. *Adv Data.* 2000;(314):1-27.
30
31 25. ACOG Committee Opinion No 579: Definition of term pregnancy. *Obstet Gynecol.*
32 2013;122(5):1139-1140.
33
34 26. Lu E, Wang BW, Guimond C, et al. Disease-modifying drugs for multiple sclerosis
35 in pregnancy: a systematic review. *Neurology.* 2012;79(11):1130-1135.
36
37 27. Amato MP, Portaccio E, Ghezzi A, et al. Pregnancy and fetal outcomes after
38 interferon-beta exposure in multiple sclerosis. *Neurology.* 2010;75(20):1794-1802.
39
40 28. Boskovic R, Wide R, Wolpin J, et al. The reproductive effects of beta interferon
41 therapy in pregnancy: a longitudinal cohort. *Neurology.* 2005;65(6):807-811.
42
43 29. Weber-Schoendorfer C, Schaefer C. Multiple sclerosis, immunomodulators, and
44 pregnancy outcome: a prospective observational study. *Mult Scler.*
45 2009;15(9):1037-1042.
46
47 30. Patti F, Cavallaro T, Lo FS, et al. Is in utero early-exposure to interferon beta a risk
48 factor for pregnancy outcomes in multiple sclerosis? *J Neurol.* 2008;255(8):1250-
49 1253.
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 31. Hellwig K, Haghikia A, Rockhoff M, et al. Multiple sclerosis and pregnancy:
4 experience from a nationwide database in Germany. *Ther Adv Neurol Disord*.
5 2012;5(5):247-253.
6
7
- 8 32. Tomczyk S, Richman S, Wallace K, et al. Final results from the AVONEX
9 (intramuscular-beta-1a) pregnancy exposure registry. Presented at the Annual
10 Meeting of the European Society for Research and Treatment in Multiple Sclerosis.
11 Lyon, France. October 10-13. 2012.
12
- 13 33. Tomczyk S, Sperling B. Post-marketing pregnancy outcomes in patients exposed
14 to intramuscular-interferon-beta-1a. Presented at the Annual Meeting of the
15 European Committee for Treatment and Research in Multiple Sclerosis. Lyon,
16 France. October 10-13. 2012.
17
18
- 19 34. Hughes S, Spelman T, Gray O, et al. Exposure to interferon-beta therapy in early
20 pregnancy: a literature review of pregnancy outcomes in women with multiple
21 sclerosis. *J Neurol Neurosurg Psychiatry*. 2012;83:Supple 2 A17.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Final results from the Betaseron® (interferon beta-1b) Pregnancy Registry: a**
4 **prospective observational study of birth defects and pregnancy-related adverse**
5 **events**
6
7

8
9 **Authors:** PK Coyle, MD;¹ SM Sinclair, PhD, MPH, RN;² AE Scheuerle, MD;³ JM Thorp
10 Jr, MD;⁴ JD Albano, PhD, MPH;⁵ MJ Rametta, DO⁶
11
12

13
14 ¹Stony Brook University Department of Neurology and MS Comprehensive Care Center,
15 Stony Brook, NY
16

17 ²University of North Carolina Wilmington, Clinical Research Program, Wilmington, NC
18

19 ³Tesserae Genetics, Medical Genetics, Dallas, TX
20

21 ⁴University of North Carolina Schools of Medicine and Public Health, Department of
22 Obstetrics and Gynecology, Chapel Hill, NC
23

24 ⁵INC Research LLC, Post Approval and Strategic Services, Raleigh, NC
25

26 ⁶Bayer HealthCare Pharmaceuticals, US Medical Affairs, Neurology, Whippany, NJ
27
28
29

30 **Correspondence to:**

31 Name: Patricia Coyle

32 Affiliation: Stony Brook University and MS Comprehensive Care Center

33 Address: HSC T12-020; SUNY at Stony Brook, Stony Brook, NY 11794-8121

34 Telephone number: 631-444-8188

35 Fax number: 631-444-1474

36 Email address: patricia.coyle@stonybrookmedicine.edu
37
38
39
40
41
42
43

44 **Search terms:** multiple sclerosis, interferon beta-1b, pediatrics, pregnancy, congenital
45 abnormalities
46
47
48

49 **Word count:** 2,784 words
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objectives: Women with multiple sclerosis are often diagnosed and treated during their reproductive years. Limited data are available on the safety of treatment during pregnancy. The Betaseron® Pregnancy Registry prospectively monitored women exposed to interferon beta-1b (IFNB-1b) during pregnancy to estimate the rates of birth defects, spontaneous abortions (SABs), and other negative outcomes in this population.

Design: From 2006-2011, this observational registry enrolled women exposed prior to conception or during pregnancy (but prior to or without abnormalities on prenatal screening). Follow-up continued from enrollment through the 4-month pediatric visit.

Setting: Patients in the United States who met these criteria were enrolled in the registry.

Results: The registry enrolled 99 pregnant women; 3 were lost to follow up. The earliest exposure to IFNB-1b occurred during the first trimester for 95 pregnancies and the third trimester for 1 pregnancy. There were 99 birth outcomes (3 twins), including 86 (86.9%) live births, 11 (11.1%) SABs, and 2 (2.0%) stillbirths. Birth defects were reported in 5 (5.1%) cases. Rates of birth defects and SAB were not significantly different from population comparators. No developmental concerns were identified at the 4 month pediatric visit.

Conclusions: The small sample size limits the ability to draw definitive conclusions; however, there was no pattern to suggest increased negative outcomes with IFNB-1b.

ARTICLE SUMMARY

Strengths and limitations of this study

- The Betaseron Pregnancy Registry contains the largest sample of interferon beta-1b-exposed pregnancies collected to date
- The relatively small sample size limits the ability to draw definitive conclusions; however, there was no pattern to suggest increased negative outcomes with interferon beta-1b
- Limitations of the Betaseron Pregnancy Registry include the potential for underreporting or differential reporting of outcomes due to the exclusion of retrospective patients and the voluntary nature of participation
- Birth defect ascertainment was limited to data obtained from reporting health care providers; infants were not examined directly as part of the registry
- Data on infant outcomes were only collected for up to 4 months, reducing the ability of the registry to measure developmental progress, defects diagnosed beyond 4 months of age, and resolution of suspected defects reported in early infancy

INTRODUCTION

Multiple sclerosis (MS) is a chronic demyelinating and neurodegenerative disorder that affects over 400,000 people in the United States.^{1,2} MS is much more common in women than men, and diagnosis frequently occurs when patients are in their 20s and 30s.^{3,4} Consequently, women of child-bearing age constitute a considerable portion of all patients with MS. Furthermore, up to 10% have disease onset during pregnancy.¹

The approved disease-modifying treatments (DMTs) for patients with MS have been given pregnancy category ratings of B, C, D, or X by the US Food and Drug Administration based on clinical experience and/or preclinical data (see Table 1 for pregnancy categorizations of currently-approved DMTs and a definition of different pregnancy classifications).⁵⁻¹⁴ The safety of these agents during pregnancy is a major concern given the patient profile outlined above. However, data on pregnancy outcomes in DMT-exposed patients is limited. Among the beta interferons, this is particularly true for interferon beta-1b (Betaseron[®]/Betaferon[®]; Bayer HealthCare Pharmaceuticals; Whippany, NJ).

Table 1. Pregnancy classifications of disease modifying treatments (DMTs) approved for use by patients with MS.

| Disease-modifying therapy | Pregnancy category |
|---|--------------------|
| Glatiramer acetate (Copaxone [®]) ⁹ | B |
| Interferon beta-1b (Betaseron [®] /Betaferon [®] ; Extavia [®]) ^{5,14} | C |
| Intramuscular interferon beta-1a (Avonex [®]) ⁷ | C |

| | |
|--|---|
| Subcutaneous interferon beta-1a (Rebif [®]) ¹¹ | C |
| Fingolimod (Gilenya [®]) ⁸ | C |
| Dimethyl fumarate (Tecfidera [®]) ¹³ | C |
| Natalizumab (Tysabri [®]) ⁶ | C |
| Mitoxantrone ^{6,10} | D |
| Teriflunomide (Aubagio [®]) ^{6,10,12} | X |
| FDA pregnancy categories ¹⁵ <ul style="list-style-type: none"> • Category A: No evidence of adverse effects in studies of pregnant humans • Category B: No studies from humans, but no evidence of adverse effects in studies of pregnant animals; or negative effects observed in animal models but no evidence of adverse effects in humans • Category C: Insufficient evidence from human studies, but research with pregnant animals identified some medication-related negative outcomes; in some situations, the medication may be more beneficial than harmful • Category D: Medication-related negative outcomes in human studies but medication may be needed in some situations • Category X: Medication-related negative outcomes in human or animal studies; there are no situations in which the medicine should be used | |

No teratogenic effects were seen in studies of pregnant rhesus monkeys exposed to interferon beta-1b. However, dose-related abortifacient activity was seen at doses from 0.028 mg/kg/d to 0.42 mg/kg/d, which is 2.8 to 4.0 times the recommended human dose based on surface area comparison.⁵ Although data on human exposure during pregnancy are limited, patients are advised to discontinue treatment with interferon beta-1b if they become pregnant or plan to become pregnant.⁵ The goal of the

1
2
3 Betaseron Pregnancy Registry was to compare pregnancy outcomes in women
4
5 exposed to interferon beta-1b at conception or during pregnancy relative to general
6
7 population comparators. This is the largest observational study reported to date for
8
9 interferon beta-1b.
10
11
12
13

14 15 16 17 **METHODS**

18 19 20 **Population and outcome measures**

21
22
23 The Betaseron Pregnancy Registry was a voluntary, prospective, observational,
24
25 exposure-registration and follow-up study. Women with an existing pregnancy who had
26
27 been exposed to interferon beta-1b at any time after the first day of the last menstrual
28
29 period (LMP), or during pregnancy but before any prenatal screening (eg, ultrasound,
30
31 amniocentesis), were prospectively enrolled in the registry. Women with similar
32
33 exposure who had undergone some prenatal testing and were without abnormal
34
35 findings suggestive of fetal abnormalities were also enrolled. Given the widespread use
36
37 of early prenatal testing, restricting enrollment to women without prenatal testing would
38
39 have dramatically reduced the available population, hindering the success of the
40
41 registry.^{16,17} Because retrospective cases (ie, pregnancies submitted after the birth of
42
43 the infant or after evidence suggestive of an abnormality on prenatal tests) can be
44
45 biased toward reporting of unusual or severe outcomes, these cases and those in which
46
47 an abnormality was identified prior to registry contact were excluded.
48
49
50
51
52

53
54
55 The primary outcome measure was the rate of major congenital malformations in infants
56
57 exposed to interferon beta-1b during gestation, defined as any time after the first day of
58
59
60

1
2
3 the mother's LMP. Secondary outcome measures included the prevalence of
4
5 spontaneous abortion and other negative pregnancy outcomes in exposed women.
6
7
8 Prevalence of elective abortion, stillbirth, ectopic pregnancy, neonatal death, and
9
10 maternal death was assessed. Reporting was conducted by health care providers
11
12 (HCPs), patients, or representatives of the study sponsor. Maternal follow-up lasted
13
14 from enrollment through pregnancy outcome. Infant follow-up continued through the 4-
15
16 month pediatric visit in most cases.
17
18

19
20
21 Pregnancy outcomes were classified as live birth, spontaneous abortion, elective
22
23 abortion, or fetal death/stillbirth. A live birth was defined as any delivery resulting in a
24
25 viable neonate ≥ 24 weeks of gestation. The spontaneous loss of a fetus at < 20 weeks
26
27 of gestation was classified as a spontaneous abortion. Any fetus delivered dead ≥ 20
28
29 weeks of gestation, or weighing ≥ 500 g regardless of gestational age, was classified as
30
31 a stillbirth. Fetal death occurring > 20 weeks but < 28 weeks was classified as early fetal
32
33 loss while death occurring ≥ 28 weeks was considered late fetal loss. Elective abortions
34
35 encompassed any induced or voluntary ending of the pregnancy. Other pregnancy
36
37 outcomes included ectopic pregnancies, maternal death, and neonatal death. Infant size
38
39 was classified as "small," "appropriate," or "large" for gestational age based on HCP
40
41 assessment.
42
43
44
45

46
47 Birth defects were defined as any significant structural or chromosomal defect
48
49 diagnosed with signs/symptoms using the Metropolitan Atlanta Congenital Defects
50
51 Program (MACDP) classification of birth defects, or any case with 2 or more secondary
52
53 or "conditional" abnormalities that would not have been classified as primary birth
54
55 defects by MACDP. Conditional abnormalities, some of which were also referred to as
56
57
58
59
60

1
2
3 “minor birth defects”, were included if present in a cluster of 2 or more to increase the
4 sensitivity of monitoring and to avoid missing a potential signal. Birth defects were
5 coded using an organ system classification to increase the possibility of detecting a
6 potential signal by grouping together similar defects or defects with similar etiology.¹⁸ All
7 cases were coded in accordance with both the MACDP code book and the organ
8 system classification by an expert in dysmorphology (AES) who evaluated the potential
9 temporal relationship between the exposure to interferon beta-1b and the etiology of the
10 defect, considering other potential confounders (eg, exposure to other therapies
11 received during the pregnancy, maternal or paternal history of defects, underlying
12 disease).¹⁸ Further follow-up for birth defect cases was conducted if additional
13 information was needed by the dysmorphologist or the data safety monitoring board
14 (DSMB). Defects were classified as “Defect with a known cause, temporality may be
15 irrelevant;” “No temporal association;” or “Unable to assess temporality.” Available data
16 for each defect case were reviewed individually for potential confounders and relevant
17 information was evaluated and recorded.

18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Conduct of the registry was overseen by an independent DSMB. The Western Institutional Review Board (WIRB) reviewed and approved the protocol, which included a waiver of documentation of informed consent. The Betaseron Pregnancy Registry was listed in the public trials registry (www.clinicaltrials.gov) under NCT00317564.

Statistical procedures

Analyses were conducted on all prospective evaluable cases (ie, enrolled pregnancies, not lost to follow-up, with known outcome and birth defect status). The birth defect rate

1
2
3 was calculated by dividing the number of cases with birth defects among all live births
4 and fetal losses >20 weeks gestation (numerator) by the number of live births
5 (denominator). This approach increased the sensitivity of monitoring and may have
6 overestimated the true rate; however it erred on the side of caution. Since the presence
7 or absence of birth defects is difficult to ascertain among fetal losses, including fetal
8 losses in the denominator would have biased the birth defect rate downwards. Ninety-
9 five percent exact confidence intervals (CI) were calculated for birth defect rate and
10 other point estimates. Outcome data were stratified by the earliest trimester of exposure
11 to interferon beta-1b.
12
13
14
15
16
17
18
19
20
21
22
23
24

25 Population-based external comparator groups were used to evaluate the rates of
26 spontaneous abortion and birth defects in the registry. Risk of spontaneous abortions
27 was compared with estimates for the general population of the United States from the
28 National Survey of Family Growth (NSFG), which was conducted by the National Center
29 for Health Statistics,¹⁹ using Fisher's exact test based on binomial distribution for
30 exposures. Risk of birth defects was compared with that reported by the MACDP.^{20,21}
31 This population-based birth defect surveillance system includes all infants born in the
32 metropolitan area of Atlanta, Georgia. From 1999 to 2003, the MACDP estimated the
33 population birth defect rate to be 2.78 birth defects per 100 live births in its
34 database.^{20,21}
35
36
37
38
39
40
41
42
43
44
45
46
47
48

49 When the Registry was designed and launched, it aimed to enroll approximately 420
50 pregnant women to reach the goal of 210 live births to evaluate the primary endpoint
51 (risk of birth defects). This sample size was estimated to be sufficient to rule out a 2.2-
52 fold increase in birth defects compared to the MACDP rate of 2.78^{20,21} with 80% power
53
54
55
56
57
58
59
60

1
2
3 (assuming a 5% level of significance). The sample size goal of 420 pregnancies was
4
5 expected to result in only 210 live births because of losses to follow up, enrollment
6
7 failures, and a live birth rate of 62%.¹⁷. After approximately 5 years of operation,
8
9 Registry enrollment resulted in only 99 live births.
10
11

12 13 **Role of the funding source**

14
15
16
17 The study was jointly designed by members of the DSMB and the study sponsor. The
18
19 authors, which included both the DSMB and representatives of the sponsor, had access
20
21 to all the data, participated in analysis and interpretation, and were members of the
22
23 publication committee. The decision to submit the article for publication was made
24
25 jointly by the members of the steering committee and the sponsor.
26
27
28
29
30
31
32

33 **RESULTS**

34 35 **Patient disposition**

36
37
38
39 Between April 24, 2006 and July 31, 2011, 99 pregnant women were prospectively
40
41 enrolled in the Betaseron Pregnancy Registry. Follow-up of pregnant women and their
42
43 live-born infants continued through July 16, 2012. Pregnancy outcomes were reported
44
45 for 96 exposed pregnancies, with 3 pregnancies lost to follow-up (Table 2). Initial
46
47 exposure to interferon beta-1b occurred in the first trimester for 95 patients, and in the
48
49 third trimester for 1 patient. Seventy-four patients had pediatric follow up. For the
50
51 remaining 22 patients, follow-up continued only until birth. Prenatal testing prior to
52
53 enrollment was reported in 33 cases (34.4%).
54
55
56
57
58
59
60

Table 2. Maternal demographics.

| | Analysis population (N=96) |
|--|---------------------------------------|
| Age at enrollment (years) | |
| n | 95 ^a |
| Mean (SD) | 30.9 (5.29) |
| Median (range) | 31.0 (19-44) |
| Age category, n (%) | |
| ≤19 years | 1 (1.0) |
| 20-34 years | 69 (71.9) |
| ≥35 years | 25 (26.0) |
| Missing | 1 (1.0) |
| Race/ethnicity, n (%) | |
| White | 62 (64.6) |
| Black | 25 (26.0) |
| Hispanic | 2 (2.1) |
| Asian | 0 (0) |
| Other | 6 (6.3) |
| Missing | 1 (1.0) |
| MS duration at enrollment, n (%) | |
| <1 year | 23 (24.0) |
| 1-5 years | 51 (53.1) |
| 6-10 years | 11 (11.5) |
| >10 years | 6 (6.3) |
| Missing | 5 (5.2) |
| Earliest trimester of exposure, ^b n (%) | |
| First | 95 (99.0) |
| Second | 0 (0) |

| | |
|---------------------------------------|-----------|
| Third | 1 (1.0) |
| Prenatal tests, n (%) | |
| Prenatal test(s) after enrollment | 53 (55.2) |
| Prenatal test(s) prior to enrollment | 33 (34.4) |
| Date of prenatal test(s) not provided | 1 (1.0) |
| No prenatal tests | 7 (7.3) |
| Missing/unknown | 2 (2.1) |

^a Age data were missing for 1 case.

^b First trimester exposure was initial exposure occurring from the first day of the LMP through 13 weeks gestation; third trimester exposure was initial exposure occurring in the 28th week through the end of the pregnancy.

The majority of the sample was white (62 patients [64.6%]); 25 patients (26.0%) were black. In addition, 2 patients (2.1%) were Hispanic while 6 patients were of other races/ethnicities (6.3%) and race/ethnicity data were missing for 1 patient (1.0%). Note that the distribution of race/ethnicity in the Betaseron Pregnancy Registry was different from population norms in the United States (72.4% white, 12.6% black, 16.3% Hispanic).²²

Pregnancy outcomes

From the 96 evaluable pregnancies, there was a total of 99 birth outcomes available, including 3 sets of twins. These outcomes included 86 live births, 2 stillbirths, and 11 spontaneous abortions (Table 3). Both stillbirths occurred in black women with a history of prior spontaneous abortion and other comorbidities that may have affected birth outcomes. The first case, ending in stillbirth, reported hypertension, obesity (post gastric bypass), and oligohydramnios. The second reported antiphospholipid antibody

1
2
3 syndrome, maternal human papillomavirus infection, early rupture of membranes
4 attributed to vaginal bacterial infection, and preterm labor and delivery attributed to
5 incompetent cervix. The prevalence of spontaneous abortion in the Betaseron
6 Pregnancy Registry (11.5% [95% CI 5.9–19.6]) was not significantly different from the
7 16% estimate for the general population of the United States based on NSFG data
8 (relative risk 0.7 [95% CI 0.4–1.2], $P=0.86$, Fisher's exact test based on binomial
9 distribution for exposures).
10
11
12
13
14
15
16
17
18
19
20
21
22
23

Table 3. Pregnancy outcomes in the Betaseron Pregnancy Registry.

| Outcomes, n (% , 95% CI) | Interferon beta-1b– exposed pregnancies | Relative risk (RR) (95% CI) |
|-----------------------------------|--|--|
| Live births (N=96) | 83 (86.4%) | - |
| Birth defects (N=86) ^a | 5 (5.8%, 1.9–13.0) | RR (95% CI) 2.1 (0.9-4.9), $P=0.092^b$ |
| Spontaneous abortions (N=96) | 11 (11.5%, 5.9–19.6) | RR (95% CI) 0.7 (0.4–1.2) $P=0.8603^c$ |
| Stillbirth (N=96) | 2 (2.1) | - |
| Maternal deaths | 0 (0) | - |
| Infant deaths | 0 (0) | - |
| Ectopic pregnancies | 0 (0) | - |

^a Excludes spontaneous and elective abortions <20 weeks gestation with reported birth defects per MACDP convention. The denominator is restricted to live births.

^b Relative risk compared with 2.78% reported by MACDP; Fisher's exact test based on binomial distribution for exposures.^{20,21}

^c Relative risk compared with 16.0% rate of SAB reported by NSFG; Fisher's exact test.²³

1
2
3 Infant assessments were made at birth for 86 babies, up to 3 months of age for 74
4 babies, and at 4 months for 59 babies (Table 4). HCPs assessed infant size as
5 appropriate for gestational age at birth for 67 cases (77.9%). Four-month follow-up did
6 not identify any consistent pattern of developmental abnormalities. Birth defects were
7 identified in 5 cases (Table 5), resulting in a relative risk of 2.1 (95% CI 0.9–4.9). The
8 reported birth defects occurred in several different organ systems, including the
9 musculoskeletal, cardiovascular, and circulatory systems, with no pattern to the organ
10 systems affected. For all cases reporting birth defects, the earliest exposure to
11 interferon beta-1b 250 micrograms dosed every other day occurred during the first
12 trimester of gestation. No birth defects were reported among the spontaneous
13 pregnancy losses or stillbirths. The birth defect rate estimated by the Betaseron
14 Pregnancy Registry (5.8% [95% CI 1.9–13.0]) was not significantly different from that
15 reported by MACDP (2.78%, $P=.092$, Fisher's exact test). The relatively wide
16 confidence intervals, which include the MACDP rate, reflect the small sample size and
17 suggest no difference between the birth defect rate from the Betaseron Pregnancy
18 Registry and the MACDP.

19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45 **Table 4.** Infant assessments at birth and at 4 months.

| | At birth | At 4-month follow-up | Approximate median in US population at birth ²⁴ |
|-------------------|-----------|----------------------|--|
| Number of infants | 86 | 59 | |
| Sex, n (%) | | | |
| Female | 40 (46.5) | 26 (44.1) | |

| | | | |
|--|------------------|---------------|-------------|
| Male | 46 (53.5) | 33 (55.9) | |
| Infant weight, g | | | |
| Median | 3346.8 | 6747.0 | 3200-3600 |
| Range | 470.0-4593.0 | 4763.0-8902.0 | |
| Infant size, n (%) ^a | | | |
| Small | 7 (8.1) | 3 (5.1) | |
| Appropriate | 67 (77.9) | 48 (81.4) | |
| Large | 7 (8.1) | 6 (10.2) | |
| Missing | 5 (5.8) | 2 (3.4) | |
| Infant length (cm) | | | |
| Median | 50.8 | 63.5 | 49-50 |
| Range | 30.5-55.9 | 53.3-69.3 | |
| Infant head circumference (cm) | | | |
| Median | 34.3 | 41.9 | 34.8-35.8 |
| Range | 29.5-38.1 | 37.0-44.5 | |
| Gestational age at birth (weeks) | | | |
| Median | 39.0 | NA | |
| Range | 24.0-41.0 | NA | |
| <u>Gestational age at birth, n (%)^{b,c}</u> | | | |
| <u>Preterm</u> | <u>8 (10.0)</u> | <u>NA</u> | <u>9.9%</u> |
| <u>Term</u> | <u>72 (90.0)</u> | <u>NA</u> | |

^a Infant size relative to gestational age at birth and age at 4 months (± 4 weeks), respectively.

^b Gestational age at birth calculated as [(280-(corrected estimated due date – outcome date))/7]; estimated due date (EDD) was used when corrected EDD was not available. Preterm births were defined as any baby born before the end of the 36th gestational week and term births were defined as those born after ≥ 37 weeks, 0 days gestation.²⁵

^c Among singleton live births; excludes 3 twin pregnancies (6 live births) with outcomes at 24 weeks, 5 days; 36 weeks, 3 days; and 36 weeks, 5 days.

Table 5. Summary of birth defect cases

| Case | Description of the reported birth defects ^a | Organ system | Temporality assessment |
|------|---|---|--|
| 1 | Live infant, male, 34 weeks gestation 1. Trisomy 21 (Down syndrome) ^b | 1. Chromosome anomaly | 1. Defect with known cause, temporality may be irrelevant |
| 2 | Live infant, male, 40 weeks gestation 1. Hemangioma (capillary hemangioma parietal area and left 3rd toe) | 1. Circulatory system | 1. Unable to assess temporality |
| 3 | Live infant, female, 39 weeks gestation 1. Hip dysplasia (defect) 2. Patent foramen ovale (conditional defect) 3. Patent ductus arteriosus (conditional defect) 4. Ventriculoseptal defect (defect) | 1. Other musculoskeletal defects 2. Heart 3. Circulatory system 4. Heart | 1. Unable to assess temporality 2. Defect with known cause, temporality may be irrelevant 3. Defect with known cause, temporality may be irrelevant 4. Defect with known cause, temporality may be irrelevant |
| 4 | Live infant, male, 36 weeks gestation 1. Abnormal shape of the head without craniosynostosis | 1. Musculoskeletal defects | 1. No temporal association |
| 5 | Live infant, male, 38 weeks gestation 1. Polydactyly | 1. Limb reduction/addition defects | 1. No temporal association |

^a Gestational age data are birth ages, not age at exposure.

^b The mother of this infant was older than 35 years of age.

1
2
3 Because of the relatively high percentage of black patients in the Betaseron Pregnancy
4 Registry, a subanalysis of pregnancy outcome data was conducted to compare black
5 and non-black patients. No significant differences were seen between these two
6 populations in the rates of birth defects or rates of spontaneous abortion. However,
7 small sample sizes in this subanalysis limit the conclusions that can be drawn from
8 these data.
9
10
11
12
13
14
15
16
17
18
19
20
21

22 **DISCUSSION**

23
24 This Betaseron Pregnancy Registry reported 99 outcomes in 96 evaluable pregnancies
25 (including 3 twin pregnancies), consisting of 86 live births, 2 stillbirths, and 11
26 spontaneous abortions. There were 5 cases with birth defects. Among these 5 cases
27 were a variety of birth defects which were not clustered around a single type of defect or
28 effected organ system. In addition, 2 of these cases had defects that were not
29 temporally related to interferon beta-1b exposure (ie, the timing of the exposure was not
30 consistent with the development of the defect) and 1 had a chromosomal abnormality
31 potentially related to advanced maternal age that was classified as having no temporal
32 association to exposure. This lack of a consistent pattern suggests that there was no
33 signal for birth defects due to interferon beta-1b exposure. The risk of spontaneous
34 abortion or birth defect was not significantly different from comparator populations. In
35 addition, no elective abortions or maternal deaths were observed and there were no
36 abnormalities in rate of prematurity or in birth weight/size. These data represent the
37 largest cohort of interferon beta-1b-exposed patients reported to date; however, the
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 sample size was still smaller than necessary to have sufficient statistical power to draw
4
5 definitive conclusions.
6
7

8
9 To date, several publications have discussed the results of exposure to interferon beta
10
11 formulations during pregnancy; however none have exclusively examined interferon
12
13 beta-1b exposure. A recent review of this literature suggested that beta interferons may
14
15 be associated with some negative outcomes,²⁶ a conclusion that contrasts with the
16
17 findings presented here. Three studies, also with small sample sizes, (N=88, N=69, and
18
19 N=23) found low birth weight in infants exposed to interferon beta formulations (either
20
21 interferon beta-1a or beta-1b) during gestation.²⁷⁻²⁹ Another study (N=14) found
22
23 evidence of prematurity with interferon beta exposure, but birth weight was not
24
25 significantly lower than unexposed comparators.³⁰ However, another study (N=63) did
26
27 not find evidence of low birth weight following interferon beta exposure.³¹ Other negative
28
29 pregnancy outcomes, including a higher rate of spontaneous abortion and shorter mean
30
31 birth length, have also been associated with exposure to interferon beta
32
33 formulations.^{27,28}
34
35
36
37
38
39

40
41 In contrast, the Betaseron Pregnancy Registry did not find any patterns to suggest
42
43 negative pregnancy outcomes associated with interferon beta-1b exposure. It should be
44
45 noted that the 5 aforementioned studies combined subjects exposed to either interferon
46
47 beta-1a or beta-1b into a single group.²⁷⁻³¹ Two of these studies did not provide
48
49 separate numbers of interferon beta-1a and beta-1b-exposed patients.^{27,29} In the 3
50
51 studies that divided exposure groups into interferon beta-1a and beta-1b, patients with
52
53 interferon beta-1b monotherapy exposure numbered only 10–21^{28,30,31}, thereby limiting
54
55 the statistical power to draw conclusions about the effects of interferon beta-1b on
56
57
58
59
60

1
2
3 pregnancy outcomes. The Betaseron Pregnancy Registry data reported here have the
4 advantage of a much larger sample size (99 outcomes), albeit much lower than planned
5 when the registry was designed.
6
7
8
9

10
11 The Betaseron Pregnancy Registry included pediatric follow-up, which has not been not
12 consistently reported in other studies: only 2 other studies have assessed pediatric
13 outcomes.^{27,30} The first (N=14) reported normal development of interferon beta-1a- or
14 beta-1b-exposed infants up to the 12-month milestones (walking and talking).³⁰ A later
15 study (N=88) found no developmental abnormalities in interferon beta-exposed infants
16 after 2.1 years of follow-up.²⁷ The Betaseron Pregnancy Registry's findings are
17 consistent with these previous reports and reinforce the hypothesis that there are no
18 obvious postnatal effects from in utero interferon beta-1b exposure.
19
20
21
22
23
24
25
26
27
28
29

30
31 The potential risks associated with interferon beta-1b exposure during pregnancy, which
32 were not found to be significantly different from comparator cohorts in this study, need
33 to be considered along with the risks for patients with MS who remain untreated during
34 pregnancy. Prior research suggested that MS itself was not associated with increased
35 risk for negative pregnancy outcomes.¹ However, risk for relapses is higher after
36 delivery, with 20%–40% of patients experiencing a clinical relapse or worsening of the
37 disease in the first 3 months postpartum.¹
38
39
40
41
42
43
44
45
46
47

48
49 The results reported here are similar to 2 recent presentations related to intramuscular
50 interferon beta-1a exposure during pregnancy. In the first, no pattern suggestive of
51 increased negative outcomes was found in 306 pregnancies in the Avonex Pregnancy
52 Exposure Registry.³² Similarly, post marketing surveillance (N=552) found the rate of
53
54
55
56
57
58
59
60

1
2
3 spontaneous abortion was consistent with the general population, with no evidence of
4 increased birth defect rates.³³ Together with the Betaseron Pregnancy Registry, the
5 preponderance of data suggest no pattern of increased negative outcomes for women
6 and infants exposed to interferon beta formulations during pregnancy, a finding that was
7 supported by a recent review of the literature related to interferon beta exposure during
8 pregnancy (N=1105).³⁴
9
10
11
12
13
14
15
16

17
18 This is also the first study to report on pregnancy exposure outcomes in black patients
19 with MS. No differences were noted based on race.
20
21
22

23
24 Limitations of the Betaseron Pregnancy Registry include the potential for underreporting
25 or differential reporting of outcomes due to the exclusion of retrospective patients.
26
27

28 However, it is important to note that data from these retrospective patients were
29 captured through post-marketing surveillance efforts. In addition, birth defect
30 ascertainment was limited to voluntary reports from health care providers (not unlike
31 population-based public health surveillance programs), which potentially limited the
32 level of detail needed to fully characterize a birth defect case and rule out missed or
33 misdiagnoses. Lastly, data on infant outcomes were only collected for up to 4 months,
34 reducing the ability of the registry to measure developmental progress.
35
36
37
38
39
40
41
42
43
44

45
46 Due to low sample size, definitive conclusions cannot be drawn from the Betaseron
47 Pregnancy Registry data. However, there was no pattern to suggest an increased risk of
48 birth defects in infants or an increased rate of spontaneous abortions in women after
49 exposure to interferon beta-1b during pregnancy. Infant assessments, such as birth
50 weight, birth length, and head circumference, also did not differ from population
51
52
53
54
55
56
57
58
59
60

1
2
3 estimates and the 4 month infant follow-up did not identify any developmental concerns.
4
5 Continued monitoring through routine post-marketing surveillance activities is
6
7 recommended.
8
9

10 11 **ACKNOWLEDGMENTS**

12
13
14 We are grateful to the patients and their healthcare providers for their contributions to
15
16 the study. Additionally, we thank Robert C. Ristuccia, PhD (Precept Medical
17
18 Communications), for assistance with preparation of the manuscript (funded by Bayer
19
20 HealthCare Pharmaceuticals).
21
22
23
24
25
26

27 **COMPETING INTERESTS**

- 28
29
30 • PK Coyle has received compensation for consulting/educational activities from
31
32 Aconda, Accordant, Bayer, Biogen Idec, Genentech/Roche, Genzyme/Sanofi
33
34 Aventis, Merck-Serono, Mylan, Novartis, and Teva Neurosciences. She has
35
36 received research funding from Actelion, Novartis, and Opexa.
37
38
- 39 • S Sinclair Roberts has received compensation for consulting activities from
40
41 Bayer, Lilly, and INC Research.
42
43
- 44 • AE Scheuerle has received compensation for consulting activities from Abbott,
45
46 Amylin, Bayer, Biogen Idec, INC Research, Genentech, Novartis, PPD, TAP
47
48 Pharma, Roche, Teva, and UCB Pharma.
49
50
- 51 • JM Thorp has received compensation for consulting from Bayer,
52
53 GlaxoSmithKline, and PPD.
54
55
56
57
58
59
60

- JD Albano is an employee of INC Research, the coordinating center for the Betaseron Pregnancy Registry.
- MJ Rametta is a salaried employee of Bayer HealthCare.

AUTHOR CONTRIBUTIONS

- PK Coyle: Interpreted data and actively contributed to the writing and reviewing of the submitted manuscript. Member of the data safety monitoring board
- SM Sinclair: Interpreted data and actively contributed to the writing and reviewing of the submitted manuscript. Member of the data safety monitoring board
- AE Scheuerle: Interpreted data and actively contributed to the writing and reviewing of the submitted manuscript. Member of the data safety monitoring board
- JM Thorp: Interpreted data and actively contributed to the writing and reviewing of the submitted manuscript. Member of the data safety monitoring board
- [JD](#) Albano: Provided oversight for the conduct of the study, including the statistical analysis, interpreted data, and actively contributed to the writing and reviewing of the manuscript
- MJ Rametta: Interpreted data and actively contributed to the writing and reviewing of the submitted manuscript. Sponsor's responsible clinician for registry

This study was funded by Bayer HealthCare Pharmaceuticals, Inc.

References

1. Bennett KA. Pregnancy and multiple sclerosis. *Clin Obstet Gynecol*. 2005;48(1):38-47.

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
2. Vlahiotis A, Sedjo R, Cox ER, Burroughs TE, Rauchway A, Lich R. Gender differences in self-reported symptom awareness and perceived ability to manage therapy with disease-modifying medication among commercially insured multiple sclerosis patients. *J Manag Care Pharm.* 2010;16(3):206-216.
 3. Compston A, Coles A. Multiple sclerosis. *Lancet.* 2002;359(9313):1221-1231.
 4. Coyle PK, Christie S, Fodor P, et al. Multiple sclerosis gender issues: clinical practices of women neurologists. *Mult Scler.* 2004;10(5):582-588.
 5. Betaseron [package insert]. Montville, NJ: Bayer HealthCare Pharmaceuticals; 2010.
 6. Tysabri [package insert]. Cambridge, MA: Biogen Idec Inc; 2012.
 7. Avonex [package insert]. Cambridge, MA: Biogen Idec Inc; 2012.
 8. Gilenya [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2012.
 9. Copaxone [package insert]. Kansas City, MO: TEVA Neuroscience; 2012.
 10. Mitoxantrone [package insert]. Kansas City, MO: TEVA Neurosciences; 2012.
 11. Rebif [package insert]. Rockland, MA: EMD Serono; 2012.
 12. Aubagio [package insert]. Cambridge, MA: Genzyme Corporation; 2012.
 13. Tecfidera [package insert]. Cambridge, MA: Biogen Idec Inc; 2013.
 14. Extavia [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2012.
 15. US Department of Health and Human Services OoWH. Pregnancy and Medicines. Available at <http://www.womenshealth.gov/publications/our-publications/fact-sheet/pregnancy-medicines.pdf>. Accessed December 21, 2012.
 16. Covington D, Roberts S, McKain L. Impact of prenatal testing on birth defect prevalence in pregnancy exposure registries. *Pharmacoepidemiol Drug Saf.* 2008;17(Supplement 1):S13.
 17. US Food and Drug Administration. Guidance for industry establishing pregnancy exposure registries. Available at <http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/WomensHealthResearch/UCM133332.pdf>. Accessed February 2014.
 18. Scheuerle A, Tilson H. Birth defect classification by organ system: a novel approach to heighten teratogenic signalling in a pregnancy registry. *Pharmacoepidemiol Drug Saf.* 2002;11(6):465-475.

19. Jones RK, Kost K. Underreporting of induced and spontaneous abortion in the United States: an analysis of the 2002 National Survey of Family Growth. *Stud Fam Plann.* 2007;38(3):187-197.
20. Correa A, Cragan J, Kucik J. Metropolitan Atlanta Congenital Defects Program 40th anniversary edition surveillance report: reporting birth defects surveillance data. *Birth Defects Research (Part A).* 2007;79:65-93.
21. Correa A, Cragan J, Kucik J, et al. Errata. *Birth Defects Research (Part A).* 2008;82(1):41-62.
22. U.S.Census Bureau. Overview of race and Hispanic origin: 2010. <http://www.census.gov/prod/cen2010/briefs/c2010br-02.pdf>. Accessed April 2013.
23. Jones CA, Pohar SL, Warren S, Turpin KV, Warren KG. The burden of multiple sclerosis: a community health survey. *Health Qual Life Outcomes.* 2008;6:1.
24. Kuczumski RJ, Ogden CL, Grummer-Strawn LM, et al. CDC growth charts: United States. *Adv Data.* 2000;(314):1-27.
25. ACOG Committee Opinion No 579: Definition of term pregnancy. *Obstet Gynecol.* 2013;122(5):1139-1140.
26. Lu E, Wang BW, Guimond C, Synnes A, Sadovnick D, Tremlett H. Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review. *Neurology.* 2012;79(11):1130-1135.
27. Amato MP, Portaccio E, Ghezzi A, et al. Pregnancy and fetal outcomes after interferon-beta exposure in multiple sclerosis. *Neurology.* 2010;75(20):1794-1802.
28. Boskovic R, Wide R, Wolpin J, Bauer DJ, Koren G. The reproductive effects of beta interferon therapy in pregnancy: a longitudinal cohort. *Neurology.* 2005;65(6):807-811.
29. Weber-Schoendorfer C, Schaefer C. Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study. *Mult Scler.* 2009;15(9):1037-1042.
30. Patti F, Cavallaro T, Lo FS, et al. Is in utero early-exposure to interferon beta a risk factor for pregnancy outcomes in multiple sclerosis? *J Neurol.* 2008;255(8):1250-1253.
31. Hellwig K, Haghikia A, Rockhoff M, Gold R. Multiple sclerosis and pregnancy: experience from a nationwide database in Germany. *Ther Adv Neurol Disord.* 2012;5(5):247-253.
32. Tomczyk S, Richman S, Wallace K, Liu S, Sperling B. Final results from the AVONEX (intramuscular-beta-1a) pregnancy exposure registry. Presented at the

1
2
3 Annual Meeting of the European Society for Research and Treatment in Multiple
4 Sclerosis. Lyon, France. October 10-13. 2012.
5

- 6
7 33. Tomczyk S, Sperling B. Post-marketing pregnancy outcomes in patients exposed
8 to intramuscular-interferon-beta-1a. Presented at the Annual Meeting of the
9 European Committee for Treatment and Research in Multiple Sclerosis. Lyon,
10 France. October 10-13. 2012.
11
- 12 34. Hughes S, Spelman T, Gray O, et al. Exposure to interferon-beta therapy in early
13 pregnancy: a literature review of pregnancy outcomes in women with multiple
14 sclerosis. *J Neurol Neurosurg Psychiatry*. 2012;83:Supple 2 A17.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

STROBE Statement—checklist of items that should be included in reports of observational studies

| | Item No | Recommendation |
|------------------------------|---------|---|
| Title and abstract | 1 | (a) Indicate the study's design with a commonly used term in the title or the abstract Title includes the word "registry." (b) Provide in the abstract an informative and balanced summary of what was done and what was found - complete |
| Introduction | | |
| Background/rationale | 2 | Explain the scientific background and rationale for the investigation being reported Paragraph 1 on page 4 |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses Paragraph on page 5 |
| Methods | | |
| Study design | 4 | Present key elements of study design early in the paper Pages 6-8 |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection Paragraph 2 on page 6; paragraph 1 on page 9 |
| Participants | 6 | (a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up Paragraph 2-3, page 6 |
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable Paragraph 2, page 6; paragraph 1-2 on page 7 |
| Data sources/ measurement | 8* | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group Paragraph 2, page 6 |
| Bias | 9 | Describe any efforts to address potential sources of bias Paragraph 3, page 7 |
| Study size | 10 | Explain how the study size was arrived at Paragraph 2, page 9 |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why Paragraph 2, page 8 |
| Statistical methods | 12 | (a) Describe all statistical methods, including those used to control for confounding Paragraph 2, page 8 (b) Describe any methods used to examine subgroups and interactions Paragraph 2, page 8 |

Continued on next page

Results

| | | |
|------------------|-----|--|
| Participants | 13* | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed Paragraph 2, page 9 |
| | | (b) Give reasons for non-participation at each stage Paragraph 2, page 9 |
| | | (c) Consider use of a flow diagram |
| Descriptive data | 14* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders Paragraph 2, page 9; paragraph 1 page 10; Table 2 |
| | | (b) Indicate number of participants with missing data for each variable of interest Paragraph 2, page 9; Table 2 |
| Outcome data | 15* | <i>Cohort study</i> —Report numbers of outcome events or summary measures over time Pages 11-15 |
| Main results | 16 | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included - NA Paragraph 2, page 9 |
| | | (b) Report category boundaries when continuous variables were categorized - NA Paragraph 2, page 9 |
| | | (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period - NA Paragraph 2, page 9 |
| Other analyses | 17 | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses Paragraph 1, page 16 |

Discussion

| | | |
|------------------|----|--|
| Key results | 18 | Summarise key results with reference to study objectives Paragraph 2, page 16 |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias Paragraph 1, page 16; paragraph 1, page 18 |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence Paragraph 2, page 18 |
| Generalisability | 21 | Discuss the generalisability (external validity) of the study results Paragraph 2, page 18 |

Other information

| | | |
|---------|----|--|
| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based Paragraph 1, page 8 |
|---------|----|--|

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

1
2 **Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and
3 published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely
4 available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at
5 <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is
6 available at www.strobe-statement.org.
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only